[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 531
1. Saoji V, Chaudhari S, Gohokar D: Primary systemic amyloidosis: three different presentations. Indian J Dermatol Venereol Leprol; 2009 Jul-Aug;75(4):394-7
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary systemic amyloidosis: three different presentations.
  • Primary systemic amyloidosis is a rare disease.
  • We report three cases of primary systemic amyloidosis, one case with multiple myeloma and two cases without any hematological abnormality.
  • [MeSH-major] Amyloidosis / complications. Amyloidosis / diagnosis. Multiple Myeloma / complications. Multiple Myeloma / diagnosis

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19584467.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


2. Toyama K, Oka H, Obata K, Ogawa H: Primary systemic amyloidosis with bloody pericardial effusion. Intern Med; 2009;48(10):821-6
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary systemic amyloidosis with bloody pericardial effusion.
  • Pathological autopsy revealed primary systemic amyloidosis.
  • There are no reports of primary systemic amyloidosis with hemorrhagic pericardial effusion.
  • [MeSH-major] Amyloidosis / complications. Pericardial Effusion / etiology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443978.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Lestre S, Gonçalves A, João A, Ferreira A, Apetato M: [Purpura: primary systemic amyloidosis manifestation]. Acta Med Port; 2009 May-Jun;22(3):307-12
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Purpura: primary systemic amyloidosis manifestation].
  • Primary Systemic Amyloidosis (AL) is the most frequent form of systemic amyloidosis and its morbilility is associated with immunoglobulin light chains deposition in vital organs.
  • In the systemic work-up, we highlight a proteinúria > 1g/24h with Bence Jones proteins and the presence of monoclonal immunoglobulin light chain (lambda type) in serum immunoelectrophoresis.
  • With the diagnosis of primary systemic amyloidosis, treatment with prednisolone and melphalan was started.
  • [MeSH-major] Amyloidosis / complications. Purpura / etiology

  • Genetic Alliance. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19686633.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


Advertisement
4. Ahmad QM, Sultan SJ, Shah IH, Sameem F: Systemic amyloidosis presenting as mucocutaneous bullous lesions. Hematol Oncol Stem Cell Ther; 2009;2(3):418-21
Hazardous Substances Data Bank. C.I. DIRECT RED 28 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic amyloidosis presenting as mucocutaneous bullous lesions.
  • Examination and tests in this patient also revealed anemia, hepatomegaly, infiltrative cardiomyopathy, polyneuropathy and immunoglobulin l deposition, favoring a diagnosis of primary amyloidosis (AL type).
  • The present case is reported in view of the rarity of the bullous variant of primary systemic amyloidosis as well as presence of mucosal lesions and a positive Nikolsky sign.
  • [MeSH-major] Amyloidosis / diagnosis. Blister / pathology. Mucous Membrane / pathology. Skin Diseases, Vesiculobullous / diagnosis

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139056.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 3U05FHG59S / Congo Red
  •  go-up   go-down


5. Porrata LF, Gertz MA, Litzow MR, Lacy MQ, Dispenzieri A, Inwards DJ, Ansell SM, Micallef IN, Gastineau DA, Elliott M, Hogan WJ, Hayman SR, Tefferi A, Markovic SN: Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res; 2005 Feb 1;11(3):1210-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis.
  • The relationship of ALC-15 with clinical outcomes in primary systemic amyloidosis is unknown.
  • EXPERIMENTAL DESIGN: We evaluated 145 consecutive patients with primary systemic amyloidosis who underwent ASCT at the Mayo Clinic from 1996 to 2003.
  • CONCLUSIONS: ALC-15 > or = 500 cells/microL is associated with significantly improved clinical outcomes following ASCT in patients with primary systemic amyloidosis.
  • [MeSH-major] Amyloidosis / therapy. Hematopoietic Stem Cell Transplantation. Lymphocytes / cytology

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709191.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Mera Menéndez F, Alvarez Carrillo S, Hinojar Gutiérrez A, Nieto S, Raboso García-Baquero E: [Primary systemic amyloidosis with exclusive involvement of the tongue as an exceptional cause of dysphagia]. Acta Otorrinolaringol Esp; 2008 Nov;59(9):469-71
MedlinePlus Health Information. consumer health - Tongue Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary systemic amyloidosis with exclusive involvement of the tongue as an exceptional cause of dysphagia].
  • We present a 73-year-old woman with progressive dysphagia and dysarthria over two years associated with systemic symptoms including weight loss, asthenia and dyspnoea.
  • [MeSH-major] Amyloidosis / complications. Amyloidosis / pathology. Deglutition Disorders / etiology. Tongue Diseases / pathology


7. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M: Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol; 2005 Feb 15;95(4):535-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement.
  • The electrocardiograms of 127 patients with primary systemic amyloidosis and biopsy-proved cardiac involvement were analyzed.
  • [MeSH-major] Amyloidosis / diagnosis. Cardiomyopathies / diagnosis. Electrocardiography. Myocardium / pathology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15695149.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 622242
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


8. Kelly JJ: Neurologic complications of primary systemic amyloidosis. Rev Neurol Dis; 2006;3(4):173-81
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurologic complications of primary systemic amyloidosis.
  • The deposits in primary systemic amyloidosis are derived from monoclonal serum proteins in plasma cell dyscrasia, which are degraded locally in tissues and deposited in insoluble sheets that damage organs.
  • The cause of organ damage in amyloidosis is unclear but most likely due to the direct toxic effects of amyloid.
  • [MeSH-major] Amyloidosis / complications

  • Genetic Alliance. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17224900.001).
  • [ISSN] 1545-2913
  • [Journal-full-title] Reviews in neurological diseases
  • [ISO-abbreviation] Rev Neurol Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


9. Gutierrez A, Turkewitz LJ, Correa H, England JD: Primary systemic amyloidosis presenting with demyelinating features. Neurol Neurophysiol Neurosci; 2006;:6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary systemic amyloidosis presenting with demyelinating features.
  • PURPOSE: Primary systemic amyloidosis is a rare disorder that has multisystemic manifestations.
  • The most common neuropathy in systemic amyloidosis is a small-fiber axonal polyneuropathy.
  • The diagnosis of systemic amyloidosis may be more difficult when patients present with an atypical polyneuropathy.
  • METHODS: Two cases of primary systemic amyloidosis with a multifocal polyneuropathy with demyelinating features are presented.
  • RESULTS: The patients reported in this series with autopsy proven amyloidosis had evidence of a polyneuropathy with demyelinating features.
  • CONCLUSIONS: Amyloidosis should be considered in the differential when a patients presents with a polyneuropathy that has demyelinating features.
  • [MeSH-major] Amyloidosis / complications. Amyloidosis / diagnosis. Demyelinating Diseases / diagnosis. Demyelinating Diseases / etiology. Polyneuropathies / diagnosis. Polyneuropathies / etiology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17260083.001).
  • [ISSN] 1933-1266
  • [Journal-full-title] Neurology, neurophysiology, and neuroscience
  • [ISO-abbreviation] Neurol Neurophysiol Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid; 0 / Immunoglobulin Subunits
  •  go-up   go-down


10. Alhaddab M, Srolovitz H, Rosen N: Primary systemic amyloidosis presenting as extensive cutaneous ulceration. J Cutan Med Surg; 2006 Sep-Oct;10(5):253-6
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary systemic amyloidosis presenting as extensive cutaneous ulceration.
  • BACKGROUND: We report a case of primary systemic amyloidosis in a 78-year-old Caucasian woman presented as a nonhealing ulcer on the right thigh for 3 months.
  • OBJECTIVE: This case represents a very unusual presentation of primary systemic amyloidosis, one in which the cutaneous manifestations provided the first signs of a devastatingly widespread multiorgan infiltration of amyloid protein.
  • [MeSH-major] Amyloidosis / diagnosis. Skin Ulcer / diagnosis

  • Genetic Alliance. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17234110.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Ray S, Pavithran K, Nair PS: Cranial neuropathy and bone involvement in primary systemic amyloidosis. J Assoc Physicians India; 2006 Jul;54:577-80
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cranial neuropathy and bone involvement in primary systemic amyloidosis.
  • Bone involvement in primary systemic amyloidosis is rare.
  • Intracranial involvement in primary amyloidosis has not been reported so far.
  • We report two cases of bone involvement in primary amyloidosis.
  • Both these cases are unique in that, destructive bone lesions with intracranial involvement and combined factor deficiencies have not been reported in primary amyloidosis previously.
  • [MeSH-major] Amyloidosis / complications. Bone Diseases / etiology. Cranial Nerve Diseases / etiology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089910.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 9008-11-1 / Interferons
  •  go-up   go-down


12. Silverstein SR: Primary, systemic amyloidosis and the dermatologist: where classic skin lesions may provide the clue for early diagnosis. Dermatol Online J; 2005;11(1):5
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary, systemic amyloidosis and the dermatologist: where classic skin lesions may provide the clue for early diagnosis.
  • Primary amyloidosis may present with skin lesions as a primary or sole expression of underlying plasma-cell dyscrasia.
  • Classic skin lesions of primary, systemic amyloidosis are listed, and features suggestive of the diagnosis are discussed.
  • [MeSH-major] Amyloidosis / diagnosis. Skin Diseases / diagnosis

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15748546.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


13. Schwarz D, Jue C, Sikov W: Primary systemic amyloidosis and persistent pleural effusions. Amyloid; 2009 Dec;16(4):239-42
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary systemic amyloidosis and persistent pleural effusions.
  • Persistent pleural effusions are not common in patients with primary systemic amyloidosis (AL).
  • We report the case of a 73-year-old woman with primary systemic AL and persistent bilateral pleural effusions, refractory to diuresis and repeated thoracenteses.
  • [MeSH-major] Amyloidosis / complications. Amyloidosis / pathology. Pleural Effusion / etiology

  • Genetic Alliance. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19922337.001).
  • [ISSN] 1744-2818
  • [Journal-full-title] Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • [ISO-abbreviation] Amyloid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Apridonidze T, Steingart R, Comenzo RL, Hoffman JE, Goldsmith Y, Liu J: Elevated troponin and abnormalities of cardiac structure and function in AL cardiac amyloidosis. J Clin Oncol; 2009 May 20;27(15_suppl):e19524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated troponin and abnormalities of cardiac structure and function in AL cardiac amyloidosis.
  • : e19524 Background: Patients with systemic amyloidosis involving the heart have generally a poor prognosis.
  • Elevated cardiac troponin (cTn) has been shown to predict poor survival in patients with AL cardiac amyloidosis (CA).
  • CONCLUSIONS: Elevated troponin in patients with AL cardiac amyloidosis is associated with worse left atrial and ventricular structure and function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960919.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Zubkov AY, Rabinstein AA, Dispenzieri A, Wijdicks EF: Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology; 2007 Sep 11;69(11):1136-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary systemic amyloidosis with ischemic stroke as a presenting complication.
  • BACKGROUND: Amyloidosis is an uncommon disorder that ultimately leads to fatal multiorgan failure.
  • The purpose of this study was to review the pathophysiologic relationship between primary systemic amyloidosis and ischemic stroke, and to determine how often stroke is the first defining manifestation.
  • METHODS: Retrospective study of 49 patients with confirmed primary amyloidosis and ischemic stroke.
  • All included patients had biopsy proven amyloidosis.
  • Ischemic strokes occurred in 13 patients (32.5%) as the initial presentation of amyloidosis.
  • Patients with initial stroke presentation had the worst outcome, with average survival of 6.9 months after established diagnosis with amyloidosis; strokes developed 9.6 months before diagnosis with primary amyloidosis.
  • CONCLUSIONS: Ischemic stroke is an underappreciated complication of primary amyloidosis.
  • In the absence of obvious clinical and cardiogenic manifestations, primary amyloidosis should be considered when echocardiography demonstrates thickening of the valves, restrictive pattern, and increased echogenicity.
  • Ischemic strokes as an initial presentation of primary amyloidosis carries a worse prognosis.
  • [MeSH-major] Amyloidosis / complications. Amyloidosis / physiopathology. Brain Ischemia / etiology. Brain Ischemia / physiopathology. Stroke / etiology. Stroke / physiopathology


16. Berk JL: Pleural effusions in systemic amyloidosis. Curr Opin Pulm Med; 2005 Jul;11(4):324-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleural effusions in systemic amyloidosis.
  • PURPOSE OF REVIEW: Large, recurrent pleural effusions in systemic amyloidoses are rare but clinically challenging events predominantly affecting patients with primary systemic amyloidosis.
  • RECENT FINDINGS: Between 1977 and 2003, the literature consisted of approximately 21-25 case reports on pleural effusions in systemic amyloidosis.
  • In 2003, Boston University published a retrospective single-center analysis of 35 primary systemic amyloidosis patients with large, refractory pleural effusions.
  • To define the role of cardiomyopathy in large, refractory pleural effusions, the Boston University Amyloid Program compared demographics, pleural fluid chemistries, echocardiographic indices, and renal function measures of the pleural effusion group with data from 120 primary systemic amyloidosis cardiomyopathy patients with no pleural effusions.
  • Neither cardiomyopathy nor nephrotic syndrome explained pleural effusions in primary systemic amyloidosis patients.
  • The large number of exudative effusions supported primary disruption of the pleural surface and its function by amyloid.
  • SUMMARY: Large pleural effusions in systemic amyloidosis occur most often in primary systemic amyloidosis, predominantly resulting from direct infiltration of the parietal pleural surface.
  • Left atrial hypertension from primary systemic amyloidosis cardiomyopathy contributes to but is not sufficient to form and sustain these effusions.
  • Secondary, familial, and senile systemic amyloidosis do not infiltrate the pleural surfaces or induce pleural effusions in a clinically significant fashion.
  • [MeSH-major] Amyloidosis / complications. Pleural Effusion / etiology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15928500.001).
  • [ISSN] 1070-5287
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


17. Roy A, Roy V: Primary systemic amyloidosis. Early diagnosis and therapy can improve survival rates and quality of life. Postgrad Med; 2006 Jun-Jul;119(1):93-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary systemic amyloidosis. Early diagnosis and therapy can improve survival rates and quality of life.
  • Primary systemic amyloidosis is a rare disease with protean manifestations.
  • Presence of nephrotic syndrome in the absence of diabetes and hypertension, cardiomyopathy in the absence of ischemia, restrictive cardiac defect, demyelinating polyneuropathy, or unexplained hepatomegaly should alert the physician to the possibility of amyloidosis.
  • Initial steps in the diagnostic evaluation of patients with suspected amyloidosis include serum and urine immunoelectrophoresis and immunofixation studies.
  • Availability of effective treatments has improved the outlook of patients with primary systemic amyloidosis.
  • [MeSH-major] Amyloidosis. Antineoplastic Agents / therapeutic use. Immunoglobulin Light Chains / metabolism. Quality of Life

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16913652.001).
  • [ISSN] 0032-5481
  • [Journal-full-title] Postgraduate medicine
  • [ISO-abbreviation] Postgrad Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunoglobulin Light Chains
  •  go-up   go-down


18. Finn BC, Young P, Silva ED, Bruetman JE, Bottaro FJ, Venditti JE, Shanley CM, Ceresetto J, Bullorsky E: [Simultaneous multiple myeloma and giant cell arteritis without systemic amyloidosis]. Medicina (B Aires); 2006;66(6):555-7
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Simultaneous multiple myeloma and giant cell arteritis without systemic amyloidosis].
  • Primary systemic amyloidosis with clinical and histopathologic features of giant cell arteritis has already been described.
  • The association of multiple myeloma (with primary amyloidosis) and giant cell arteritis is also known.
  • We present the first case in the literature of a patient with multiple myeloma and giant cell arteritis without systemic amyloidosis, suggesting a pathogenic relationship between the two diseases.
  • [MeSH-major] Amyloidosis / etiology. Giant Cell Arteritis / etiology. Multiple Myeloma / complications. Temporal Arteries / pathology


19. Gil L, Komarnicki M: [Autologous stem cell transplantation in the treatment of primary systemic amyloidosis]. Pol Merkur Lekarski; 2009 Sep;27(159):181-4
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autologous stem cell transplantation in the treatment of primary systemic amyloidosis].
  • Primary systemic amyloidosis is a plasma cell dyscrasia resulting multiorgan failure and death.
  • Current status of therapy for primary amyloidosis based on has been publication analysis.
  • Treatment options for primary amyloidosis are similar to multiple myleoma therapy.
  • Treatment of primary amyloidosis should be based on risk factors analysis.
  • In selected patients high-dose therapy and autologous stem cell transplantation has been associated with higher response rate than standard chemotherapy However, autologous transplantation for primary amyloidosis remains controversial because of high treatment-related mortality.
  • Novel non-transplant methods for primary amyloidosis therapy are highly effective.
  • Early and detailed diagnosis and treatment based on risk factors can influence survival in group of patients with systemic primary amyloidosis.
  • [MeSH-major] Amyloidosis / therapy. Hematopoietic Stem Cell Transplantation

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827724.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Editorial; English Abstract
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Myeloablative Agonists
  •  go-up   go-down


20. Leung N, Slezak JM, Bergstralh EJ, Dispenzieri A, Lacy MQ, Wolf RC, Gertz MA: Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. Am J Kidney Dis; 2005 Jan;45(1):102-11
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation.
  • BACKGROUND: Patients with primary systemic amyloidosis (AL) have a poor prognosis.
  • [MeSH-major] Acute Kidney Injury / chemically induced. Amyloidosis / complications. Amyloidosis / drug therapy. Amyloidosis / therapy. Melphalan / administration & dosage. Melphalan / adverse effects. Stem Cell Transplantation / adverse effects

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696449.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q41OR9510P / Melphalan
  •  go-up   go-down


21. Tanasilović S, Zivanović D, Nikolić M, Tomović M, Elezović I, Medenica L: [Primary systemic amyloidosis]. Vojnosanit Pregl; 2007 Dec;64(12):859-62
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary systemic amyloidosis].
  • BACKGROUND: Systemic amyloidosis is a rare disorder which usually occurs in aged persons and has a poor prognosis.
  • Systemic amyloidosis can be primary, occasionally associated with multiple myeloma, or secondary, associated with another disease.
  • CONCLUSION: This patient considered as a rare case with systemic amyloidosis highlights the importance of histopathological and physical examination in any cases with periocular purpura, petechiae, ecchymoses and macroglossia.
  • [MeSH-major] Amyloidosis / diagnosis

  • Genetic Alliance. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357912.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


22. Xavier SD, Bussoloti IF, Müller H: Macroglossia secondary to systemic amyloidosis: case report and literature review. Ear Nose Throat J; 2005 Jun;84(6):358-61
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macroglossia secondary to systemic amyloidosis: case report and literature review.
  • Amyloidosis is characterized by an abnormal extracellular deposition of amyloid in different tissues and organs, where it usually causes some type of dysfunction.
  • The two main forms of amyloidosis are systemic and localized; the latter is rare.
  • No satisfactory treatment for systemic amyloidosis has been discovered, and mean survival is poor, ranging from 5 to 15 months depending on the presence or absence of multiple myeloma.
  • We report a case of primary systemic amyloidosis in a 71-year-old man.
  • The diagnosis of amyloidosis was established by tongue biopsy, and its systemic nature was identified by analysis of aspirated abdominal fat.
  • [MeSH-major] Amyloidosis / complications. Macroglossia / diagnosis. Submandibular Gland Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Macroglossia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16075859.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


23. Seccia V, Dallan I, Cervetti G, Lenzi R, Marchetti M, Casani AP, Muscatello L: A rare case of primary systemic amyloidosis of the neck with massive cervical lymph node involvement: a case report and review of the literature. Leuk Res; 2010 Apr;34(4):e100-3
MedlinePlus Health Information. consumer health - Lymphatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of primary systemic amyloidosis of the neck with massive cervical lymph node involvement: a case report and review of the literature.
  • Amyloidosis is a term applied to a diverse group of disorders that share the deposition of amyloid protein in various extracellular tissues.
  • Systemic amyloidosis may involve almost any organ system in the body including regions in the head and neck; however, neck lymph node involvement is rare, with only five previous cases reported.
  • We present the case of a primary systemic AL amyloidosis with hepatic, cervical, retroperitoneal, axillary and inguinal lymphnode localizations, unresponsive to medical therapy and treated with a surgical approach followed by autologous bone marrow transplantation.
  • [MeSH-major] Amyloidosis / complications. Lymphatic Diseases / etiology. Neck. Otorhinolaryngologic Diseases / complications

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19931179.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] England
  • [Number-of-references] 16
  •  go-up   go-down


24. Neben-Wittich MA, Wittich CM, Mueller PS, Larson DR, Gertz MA, Edwards WD: Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J Med; 2005 Nov;118(11):1287
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis.
  • PURPOSE: The purpose of this study was to determine the prevalence of clinical syndromes and pathologic changes of myocardial ischemia due to obstructive intramural coronary amyloidosis among patients with primary amyloidosis and cardiac involvement.
  • SUBJECTS AND METHODS: Medical records and pathologic specimens were reviewed from 96 patients with primary amyloidosis and cardiac involvement at autopsy or after cardiac transplantation during a 20-year period.
  • Pathologic specimens were examined for obstructive intramural coronary amyloidosis and microscopic changes of myocardial ischemia.
  • RESULTS: Obstructive intramural coronary amyloidosis was present in 63 of 96 patients (66%).
  • Microscopic changes of myocardial ischemia were more common in patients with obstructive intramural coronary amyloidosis (86%) than in those without (52%) (P <.001).
  • In the 76 patients without coexistent severe epicardial coronary atherosclerosis, changes of myocardial ischemia were more common in those with obstructive intramural coronary amyloidosis (83%) than in those without (45%) (P <.001).
  • Syndromes of myocardial ischemia affected 16 patients (25%) with obstructive intramural coronary amyloidosis but only 2 patients (6%) without (P=.027).
  • For 11% of the patients with obstructive intramural coronary amyloidosis, a syndrome of myocardial ischemia consisting of acute myocardial infarction or angina pectoris was the first manifestation of primary amyloidosis.
  • CONCLUSION: Most patients with primary systemic amyloidosis and cardiac involvement have obstructive intramural coronary amyloidosis and associated microscopic changes of myocardial ischemia.
  • [MeSH-major] Amyloidosis / pathology. Coronary Disease / pathology. Coronary Vessels / pathology. Myocardial Ischemia / pathology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271914.001).
  • [ISSN] 1555-7162
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Sawyer DB, Skinner M: Cardiac amyloidosis: shifting our impressions to hopeful. Curr Heart Fail Rep; 2006 Jun;3(2):64-71
MedlinePlus Health Information. consumer health - Cardiomyopathy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac amyloidosis: shifting our impressions to hopeful.
  • Cardiac amyloidosis is a well-known but clinically rare cause of heart failure that has historically been associated with a poor prognosis.
  • Cardiac amyloidosis involves fibril formation from one of several underlying conditions, and the course of illness and prognosis varies among these conditions.
  • Evolving treatment strategies for patients with primary systemic amyloidosis have given this subset of cardiac amyloidosis patients a cause for hope.
  • [MeSH-major] Amyloidosis / complications. Cardiomyopathies / complications

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br Heart J. 1995 Nov;74(5):541-4 [8562243.001]
  • [Cites] Circulation. 2001 Oct 2;104(14):1594-7 [11581134.001]
  • [Cites] Pacing Clin Electrophysiol. 2001 Aug;24(8 Pt 1):1228-33 [11523608.001]
  • [Cites] Transplant Proc. 2004 Apr;36(3):643-4 [15110619.001]
  • [Cites] Semin Hematol. 1995 Jan;32(1):45-59 [7878478.001]
  • [Cites] Transplantation. 1998 Apr 15;65(7):918-25 [9565095.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1881-7 [15044258.001]
  • [Cites] Circulation. 2003 May 20;107(19):2440-5 [12719281.001]
  • [Cites] Heart. 1997 Jul;78(1):74-82 [9290406.001]
  • [Cites] Tex Heart Inst J. 2005;32(2):178-84 [16107109.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2936-8 [15070667.001]
  • [Cites] Bone Marrow Transplant. 2004 Feb;33(4):381-8 [14676787.001]
  • [Cites] Chest. 1993 Aug;104(2):618-20 [8339658.001]
  • [Cites] Lancet. 2003 May 24;361(9371):1787-9 [12781539.001]
  • [Cites] Chest. 2003 Sep;124(3):969-77 [12970025.001]
  • [Cites] Nat Struct Biol. 2000 Apr;7(4):312-21 [10742177.001]
  • [Cites] Circulation. 2005 Sep 27;112(13):2047-60 [16186440.001]
  • [Cites] Transplant Proc. 2004 Apr;36(3):645-7 [15110620.001]
  • [Cites] Transplantation. 2002 Mar 15;73(5):745-51 [11907421.001]
  • [Cites] Br J Haematol. 2004 Jun;125(6):681-700 [15180858.001]
  • [Cites] Am J Cardiol. 1985 Jun 1;55(13 Pt 1):1645 [4003314.001]
  • [Cites] Ann Intern Med. 1996 Sep 15;125(6):481-4 [8779461.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Aug 11;274(3):702-6 [10924339.001]
  • [Cites] Am J Cardiol. 1999 Nov 1;84(9):1049-54 [10569662.001]
  • [Cites] J Am Coll Cardiol. 2004 Feb 4;43(3):410-5 [15013123.001]
  • [Cites] Mayo Clin Proc. 1984 Aug;59(8):547-55 [6748745.001]
  • [Cites] Amyloid. 2003 Jun;10(2):127-9 [12964421.001]
  • [Cites] N Engl J Med. 1999 Sep 2;341(10):709-17 [10471456.001]
  • [Cites] Am J Cardiol. 2005 Feb 15;95(4):535-7 [15695149.001]
  • [Cites] Circulation. 1981 Jun;63(6):1285-8 [7014028.001]
  • [Cites] Bone Marrow Transplant. 2005 Feb;35(4):419-20 [15640825.001]
  • [Cites] Resuscitation. 2004 Jan;60(1):105-11 [14987790.001]
  • [Cites] Ann Intern Med. 2004 Jan 20;140(2):85-93 [14734330.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1817-22 [1558973.001]
  • [Cites] Am J Med. 2000 Aug 15;109(3):181-8 [10974179.001]
  • [Cites] J Heart Transplant. 1990 Jul-Aug;9(4):346-50 [2398427.001]
  • [Cites] Am J Hematol. 2005 Aug;79(4):319-28 [16044444.001]
  • [Cites] Nat Clin Pract Cardiovasc Med. 2006 Feb;3(2):110-4; quiz 115 [16446780.001]
  • [Cites] Am J Cardiol. 2005 Oct 1;96(7):982-4 [16188528.001]
  • [Cites] Circ Res. 2004 Apr 30;94(8):1008-10 [15044325.001]
  • [Cites] N Engl J Med. 2003 Aug 7;349(6):583-96 [12904524.001]
  • (PMID = 16928339.001).
  • [ISSN] 1546-9530
  • [Journal-full-title] Current heart failure reports
  • [ISO-abbreviation] Curr Heart Fail Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cardiovascular Agents
  • [Number-of-references] 41
  •  go-up   go-down


26. Schwendiman MN, Beachkofsky TM, Wisco OJ, Owens NM, Hodson DS: Primary cutaneous nodular amyloidosis: case report and review of the literature. Cutis; 2009 Aug;84(2):87-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous nodular amyloidosis: case report and review of the literature.
  • Primary cutaneous nodular amyloidosis (PCNA) is a rare form of primary cutaneous amyloidosis.
  • Recognition of this condition is of particular importance, as primary systemic amyloidosis can have a similar cutaneous presentation.
  • We report a case of PCNA in a 52-year-old woman with systemic lupus erythematosus (SLE) and Sjögren syndrome (SS).
  • We discuss the need to evaluate for systemic disease and provide a concise review of the literature focusing on clinical presentation, disease associations, and management.
  • [MeSH-major] Amyloidosis / pathology. Skin Diseases / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Humans. Lupus Erythematosus, Systemic / complications. Middle Aged. Sjogren's Syndrome / complications


27. Sattianayagam PT, Hawkins PN, Gillmore JD: Systemic amyloidosis and the gastrointestinal tract. Nat Rev Gastroenterol Hepatol; 2009 Oct;6(10):608-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic amyloidosis and the gastrointestinal tract.
  • Systemic amyloidosis is characterized by the extracellular deposition of protein in an abnormal fibrillar form.
  • Several different types of amyloidosis exist, each defined by the identity of their respective fibril precursor protein.
  • Among patients with systemic amyloidosis, histological involvement of the gastrointestinal tract is very common but is often subclinical.
  • Conversely, primary diseases of the gastrointestinal tract can cause systemic amyloidosis; for example, AA amyloidosis can occur secondary to IBD.
  • The presence and pattern of gastrointestinal symptoms varies substantially, not only between the different types of amyloidosis but also within them.
  • Currently, the aim of therapy for amyloidosis is to slow amyloid formation by reducing the abundance of the fibril precursor protein.
  • No specific treatments for the gastrointestinal symptoms of systemic amyloidosis are available; however, case reports and small published series encourage nutritional support for patients with motility disorders and pharmacological agents for treatment of diarrhea.
  • [MeSH-major] Amyloidosis / complications. Amyloidosis / metabolism. Gastrointestinal Tract / metabolism

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1982 Mar;77(3):141-5 [7081172.001]
  • [Cites] Dig Dis Sci. 1991 Dec;36(12):1756-60 [1748046.001]
  • [Cites] Semin Hematol. 1995 Jan;32(1):45-59 [7878478.001]
  • [Cites] Acta Med Scand. 1983;214(5):387-97 [6660047.001]
  • [Cites] Radiology. 1994 Jan;190(1):37-42 [8259424.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):305-6 [12145619.001]
  • [Cites] Medicine (Baltimore). 2003 Sep;82(5):291-8 [14530778.001]
  • [Cites] Acta Pathol Jpn. 1993 Jun;43(6):333-9 [8346710.001]
  • [Cites] Nature. 2002 May 16;417(6886):254-9 [12015594.001]
  • [Cites] Scand J Gastroenterol. 2000 Sep;35(9):985-9 [11063162.001]
  • [Cites] Annu Rev Med. 2006;57:223-41 [16409147.001]
  • [Cites] Digestion. 1980;20(5):351-7 [7390060.001]
  • [Cites] Am J Dig Dis. 1968 Jul;13(7):619-33 [4873279.001]
  • [Cites] Gastrointest Radiol. 1991 Spring;16(2):133-6 [2016025.001]
  • [Cites] Hum Pathol. 1985 Dec;16(12):1206-11 [4065883.001]
  • [Cites] J Gastroenterol. 2006 May;41(5):444-9 [16799886.001]
  • [Cites] Gastrointest Endosc. 1990 Jan-Feb;36(1):10-4 [2311879.001]
  • [Cites] Scand J Rheumatol. 1999;28(4):262-4 [10503567.001]
  • [Cites] Am J Gastroenterol. 2003 Oct;98(10):2219-25 [14572571.001]
  • [Cites] Gut. 1998 May;42(5):727-34 [9659172.001]
  • [Cites] Inflamm Bowel Dis. 2001 Nov;7(4):295-300 [11720318.001]
  • [Cites] Am J Med. 2001 Nov;111(7):535-40 [11705429.001]
  • [Cites] Surg Endosc. 1997 Jun;11(6):673-5 [9171133.001]
  • [Cites] Endoscopy. 1981 Jul;13(4):181-3 [7250089.001]
  • [Cites] Endoscopy. 1995 Jan;27(1):132-4 [7601026.001]
  • [Cites] Gut. 1994 Oct;35(10):1413-8 [7959197.001]
  • [Cites] Clin Physiol. 1993 Jan;13(1):57-69 [8435977.001]
  • [Cites] Digestion. 1987;36(1):13-7 [3493933.001]
  • [Cites] Gastrointest Endosc. 1994 Jan-Feb;40(1):45-50 [8163134.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Feb 28;356(1406):203-10; discussion 210-1 [11260801.001]
  • [Cites] Transplant Proc. 2008 Jan-Feb;40(1):308-9 [18261613.001]
  • [Cites] Br J Haematol. 2008 Feb;140(4):365-77 [18162121.001]
  • [Cites] Pathol Int. 2001 May;51(5):326-32 [11422789.001]
  • [Cites] Dig Dis Sci. 1996 Oct;41(10):1909-14 [8888700.001]
  • [Cites] Amyloid. 2003 Jun;10 (2):121-6 [12964420.001]
  • [Cites] Transplantation. 2004 Jan 15;77(1):64-71 [14724437.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2361-71 [17554117.001]
  • [Cites] Am J Med. 1983 Dec;75(6):951-6 [6650550.001]
  • [Cites] Arch Intern Med. 1983 Feb;143(2):247-8 [6824392.001]
  • [Cites] Amyloid. 2005 Mar;12 (1):48-53 [16076611.001]
  • [Cites] Scand J Gastroenterol. 1992;27(3):201-7 [1502482.001]
  • [Cites] N Engl J Med. 2002 Jun 6;346(23 ):1786-91 [12050338.001]
  • [Cites] Abdom Imaging. 2000 Jan-Feb;25(1):38-44 [10652919.001]
  • [Cites] Arthritis Rheum. 2007 Nov;56(11):3858-68 [17968927.001]
  • [Cites] Clin Lab Haematol. 1994 Dec;16(4):349-53 [7736713.001]
  • [Cites] Intern Med. 2006;45(20):1173-5 [17106165.001]
  • [Cites] Dig Dis Sci. 1983 Aug;28(8):763-5 [6872809.001]
  • [Cites] Lancet. 1993 May 1;341(8853):1113-6 [8097803.001]
  • [Cites] Am J Clin Nutr. 2006 Feb;83(2):350-4 [16469994.001]
  • [Cites] Ann Pathol. 2004 Jun;24(3):256-8 [15480260.001]
  • [Cites] N Engl J Med. 1979 Jul 5;301(1):24-5 [221808.001]
  • [Cites] Gastrointest Endosc. 2007 Oct;66(4):829-30; discussion 830 [17719041.001]
  • [Cites] Lancet. 2001 Jul 7;358(9275):24-9 [11454373.001]
  • [Cites] Scand J Gastroenterol. 1996 Jan;31(1):68-73 [8927943.001]
  • [Cites] Medicine (Baltimore). 1991 Jul;70(4):246-56 [2067409.001]
  • [Cites] Gastrointest Endosc. 2001 May;53(6):653-5 [11323598.001]
  • [Cites] Clin Sci (Lond). 1994 Sep;87(3):289-95 [7955904.001]
  • [Cites] Am J Nephrol. 1997;17(6):524-7 [9426849.001]
  • [Cites] QJM. 1998 Feb;91(2):141-57 [9578896.001]
  • [Cites] Endoscopy. 2006;38 Suppl 2:E15-6 [17366385.001]
  • [Cites] Gastrointest Endosc. 2008 Aug;68(2):400-1 [18402949.001]
  • [Cites] Gastroenterology. 1975 Jun;68(6):1587-92 [1132638.001]
  • [Cites] Clin Nephrol. 2005 Dec;64(6):448-51 [16370158.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Apr;87(7):2843-5 [2320592.001]
  • [Cites] JAMA. 1983 Mar 11;249(10):1322-4 [6600795.001]
  • [Cites] Eur J Radiol. 2007 Jul;63(1):105-9 [17344006.001]
  • [Cites] Clin Med (Lond). 2007 Dec;7(6):562-78 [18193704.001]
  • [Cites] Kidney Int. 1996 Jul;50(1):282-9 [8807599.001]
  • [Cites] Arthritis Rheum. 2006 Sep;54(9):2997-3000 [16947531.001]
  • [Cites] Mayo Clin Proc. 1993 Aug;68(8):763-7 [8331978.001]
  • [Cites] Int J Oral Maxillofac Surg. 1999 Apr;28(2):129-31 [10102395.001]
  • [Cites] J Intern Med. 1998 Jan;243(1):65-72 [9487333.001]
  • [Cites] Medicine (Baltimore). 1992 Sep;71(5):261-70 [1522802.001]
  • [Cites] Arch Intern Med. 1983 Dec;143(12):2325-6 [6606406.001]
  • [Cites] Gastrointest Endosc. 2004 Jan;59(1):126-9 [14722567.001]
  • [Cites] Gut. 1993 Oct;34(10):1412-7 [8244111.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):776-87 [18076735.001]
  • [Cites] J Intern Med. 1994 May;235(5):479-85 [8182405.001]
  • (PMID = 19724253.001).
  • [ISSN] 1759-5053
  • [Journal-full-title] Nature reviews. Gastroenterology & hepatology
  • [ISO-abbreviation] Nat Rev Gastroenterol Hepatol
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G7900510
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amyloid
  • [Number-of-references] 80
  •  go-up   go-down


28. Mesquita T, Chorão M, Soares I, Mello e Silva A, Abecasis P: Primary amyloidosis as a cause of microvascular angina and intermittent claudication. Rev Port Cardiol; 2005 Dec;24(12):1521-31
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary amyloidosis as a cause of microvascular angina and intermittent claudication.
  • Primary systemic amyloidosis or AL amyloidosis is a rare condition characterized by extracellular deposits of fibrils composed of fragments of immunoglobulin light chains.
  • [MeSH-major] Amyloidosis / complications. Intermittent Claudication / etiology. Microvascular Angina / etiology

  • Genetic Alliance. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566409.001).
  • [ISSN] 0870-2551
  • [Journal-full-title] Revista portuguesa de cardiologia : orgão oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology
  • [ISO-abbreviation] Rev Port Cardiol
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


29. Hoyer RJ, Leung N, Witzig TE, Lacy MQ: Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. Am J Hematol; 2007 May;82(5):409-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis.
  • Refractory pleural effusions present a challenging management problem and are associated with a poor prognosis in patients with primary systemic amyloidosis (AL).
  • [MeSH-major] Amyloidosis / complications. Antibodies, Monoclonal / therapeutic use. Pleural Effusion / drug therapy

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. METOLAZONE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. SPIRONOLACTONE .
  • Hazardous Substances Data Bank. FUROSEMIDE .
  • Hazardous Substances Data Bank. CAPTOPRIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17326106.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Diuretics; 0 / Serum Albumin; 0 / Vascular Endothelial Growth Factor A; 27O7W4T232 / Spironolactone; 2S9ZZM9Q9V / Bevacizumab; 4Z8R6ORS6L / Thalidomide; 7LXU5N7ZO5 / Furosemide; 7S5I7G3JQL / Dexamethasone; 9G64RSX1XD / Captopril; 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan; TZ7V40X7VX / Metolazone
  •  go-up   go-down


30. Siddiqui MA, Gertz M, Dean D: Amyloid goiter as a manifestation of primary systemic amyloidosis. Thyroid; 2007 Jan;17(1):77-80
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amyloid goiter as a manifestation of primary systemic amyloidosis.
  • Primary amyloidosis involving the thyroid gland is rare and limited to case reports.
  • Amyloid goiter is seen only in approximately 0.04% of patients with primary systemic amyloidosis.
  • No data is currently available regarding treatment of primary amyloidosis and its effect on the goiter.
  • However, we have evidence demonstrating that successful treatment of amyloidosis decreases thyroid enlargement and improves organ dysfunction.
  • [MeSH-major] Amyloidosis / complications. Amyloidosis / pathology. Goiter / etiology. Goiter / pathology. Thyroid Gland / pathology

  • Genetic Alliance. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274755.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Parikh S, de Lemos JA: Current therapeutic strategies in cardiac amyloidosis. Curr Treat Options Cardiovasc Med; 2005 Dec;7(6):443-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current therapeutic strategies in cardiac amyloidosis.
  • Amyloidosis is a systemic disease in which clinical manifestations are caused by the replacement of normal tissue with insoluble amyloid fibrils.
  • Cardiac magnetic resonance imaging and measurement of B-type natriuretic peptide are particularly helpful in distinguishing restrictive cardiomyopathy from constrictive pericarditis, but a tissue biopsy is required to make the diagnosis of amyloidosis.
  • Although standard treatment options for congestive heart failure may provide symptomatic relief in cardiac amyloidosis, prognosis remains dismal.
  • Therapy aimed at the underlying disease process in primary systemic amyloidosis is based on treatment regimens used in multiple myeloma, such as melphalan and prednisone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circulation. 2001 Oct 2;104(14):1594-7 [11581134.001]
  • [Cites] Am J Cardiol. 1975 Oct 6;36(4):438-44 [1190048.001]
  • [Cites] Circulation. 2003 May 20;107(19):2440-5 [12719281.001]
  • [Cites] N Engl J Med. 1997 Apr 24;336(17):1202-7 [9110907.001]
  • [Cites] Am J Cardiol. 1985 Jun 1;55(13 Pt 1):1646 [4003315.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1112-3 [10025983.001]
  • [Cites] Am Heart J. 1998 Nov;136(5):824-30 [9812077.001]
  • [Cites] Am J Cardiol. 1982 Jan;49(1):9-13 [6459025.001]
  • [Cites] Circulation. 1995 Feb 15;91(4):1269-71 [7850970.001]
  • [Cites] N Engl J Med. 1997 Feb 13;336(7):466-73 [9017939.001]
  • [Cites] Heart. 2001 Feb;85(2):202-7 [11156673.001]
  • [Cites] Blood. 1995 Aug 1;86(3):855-61 [7620181.001]
  • [Cites] J Am Coll Cardiol. 2004 Feb 4;43(3):410-5 [15013123.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92 (7):2959-63 [7708755.001]
  • [Cites] Am J Cardiol. 1977 May 4;39(5):658-64 [857628.001]
  • [Cites] Circulation. 1981 Jun;63(6):1285-8 [7014028.001]
  • [Cites] Am J Cardiol. 2000 Mar 1;85(5):664-5, A11 [11078288.001]
  • [Cites] Ann Intern Med. 2004 Jan 20;140(2):85-93 [14734330.001]
  • [Cites] Ann Intern Med. 1975 Apr;82(4):466-73 [1119764.001]
  • [Cites] Circulation. 2005 Jan 18;111(2):122-4 [15657385.001]
  • [Cites] Blood. 1998 May 15;91(10):3662-70 [9573002.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):262-7 [10458241.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1885-7 [11238135.001]
  • [Cites] N Engl J Med. 2003 Aug 7;349(6):583-96 [12904524.001]
  • (PMID = 16283971.001).
  • [ISSN] 1534-3189
  • [Journal-full-title] Current treatment options in cardiovascular medicine
  • [ISO-abbreviation] Curr Treat Options Cardiovasc Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA: The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood; 2007 Jan 15;109(2):465-70
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
  • Primary systemic amyloidosis (AL) is an incurable plasma cell disorder.
  • [MeSH-major] Amyloidosis / drug therapy. Amyloidosis / immunology. Dexamethasone / administration & dosage. Immunoglobulin Light Chains / immunology. Thalidomide / analogs & derivatives

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17008538.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 91561
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide
  •  go-up   go-down


33. Berk JL, Wiesman JF, Skinner M, Sanchorawala V: Diaphragm paralysis in primary systemic amyloidosis. Amyloid; 2005 Sep;12(3):193-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diaphragm paralysis in primary systemic amyloidosis.
  • A patient with primary (AL) systemic amyloidosis developed mononeuropathy multiplex complicated by diaphragmatic failure.
  • [MeSH-major] Amyloid Neuropathies / physiopathology. Amyloidosis / physiopathology. Respiratory Paralysis / physiopathology

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - paralysis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194876.001).
  • [ISSN] 1350-6129
  • [Journal-full-title] Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • [ISO-abbreviation] Amyloid
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL 68705
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


34. Perotti C, Del Fante C, Viarengo G, Perlini S, Vezzoli M, Rodi G, Palo A, Bergamaschi P, Salvaneschi L: Peripheral blood progenitor cell mobilization and collection in 42 patients with primary systemic amyloidosis. Transfusion; 2005 Nov;45(11):1729-34
MedlinePlus Health Information. consumer health - Kidney Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral blood progenitor cell mobilization and collection in 42 patients with primary systemic amyloidosis.
  • BACKGROUND: High-dose chemotherapy followed by an inoculum of autologous peripheral blood progenitor cells (PBPCs) can improve survival in patients affected with primary systemic amyloidosis (AL).
  • [MeSH-major] Amyloidosis / blood. Cardiomyopathies / blood. Hematopoietic Stem Cell Mobilization. Kidney Diseases / blood. Patient Care Team. Specimen Handling

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271097.001).
  • [ISSN] 0041-1132
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Demirci H, Shields CL, Eagle RC Jr, Shields JA: Conjunctival amyloidosis: report of six cases and review of the literature. Surv Ophthalmol; 2006 Jul-Aug;51(4):419-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjunctival amyloidosis: report of six cases and review of the literature.
  • Conjunctival amyloidosis is an uncommon condition that occasionally is associated with systemic involvement.
  • The clinical presentations of conjunctival amyloidosis are diverse.
  • We present six patients with conjunctival amyloidosis who were referred to us with the suspicion of another conjunctival lesion.
  • Systemic evaluation revealed primary systemic amyloidosis in one patient and no related systemic abnormalities in five patients.
  • Additionally, there was no systemic involvement in five patients.
  • In conclusion, conjunctival amyloidosis generally manifests as a yellowish-pink, hemorrhagic mass deep to the epithelium.
  • Most patients show no evidence of systemic amyloidosis.
  • [MeSH-major] Amyloidosis / pathology. Conjunctiva / pathology. Conjunctival Diseases / pathology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818085.001).
  • [ISSN] 0039-6257
  • [Journal-full-title] Survey of ophthalmology
  • [ISO-abbreviation] Surv Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


36. Mason AR, Rackoff EM, Pollack RB: Primary systemic amyloidosis associated with multiple myeloma: a case report and review of the literature. Cutis; 2007 Sep;80(3):193-200
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary systemic amyloidosis associated with multiple myeloma: a case report and review of the literature.
  • Amyloidosis is a broad and complex class of diseases that comprises several etiologies, many manifestations, and a diversity of outcomes.
  • We discuss a patient with primary systemic amyloidosis associated with multiple myeloma that illustrates many of the typical and atypical features of the disease process.
  • Despite more in-depth assessment and accurate classification, survival for patients with primary systemic disease remains poor.
  • [MeSH-major] Amyloidosis / complications. Multiple Myeloma / complications. Skin Diseases / complications


37. Martin y Porras M, Vivario M, Delfosse V, Materne P, Warling X, Hoffer E: [Cardiac amyloidosis]. Rev Med Liege; 2009 Sep;64(9):434-9
MedlinePlus Health Information. consumer health - Heart Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiac amyloidosis].
  • We present a case of a 54-year-old female presenting with renal failure and, two years later, heart failure, both due to primary systemic amyloidosis.
  • [MeSH-major] Amyloidosis / complications. Cardiomyopathy, Restrictive / etiology. Heart Failure / etiology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19947312.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


38. Fernández de Larrea C, Cibeira MT, Rovira M, Rosiñol L, Esteve J, Bladé J: Spontaneous rupture of the spleen as immediate complication in autologous transplantation for primary systemic amyloidosis. Eur J Haematol; 2008 Feb;80(2):182-4
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous rupture of the spleen as immediate complication in autologous transplantation for primary systemic amyloidosis.
  • Although splenic rupture is a recognized complication of primary amyloidosis, very few cases have been reported in the context of stem cell transplantation.
  • A patient with systemic primary amyloidosis with renal and cardiac involvement and factor X deficiency, who developed a splenic rupture 24 h after the peripheral blood stem cells infusion during autologous transplantation, is described.
  • [MeSH-major] Amyloidosis / complications. Amyloidosis / therapy. Hematopoietic Stem Cell Transplantation / adverse effects. Hematopoietic Stem Cell Transplantation / methods. Rupture, Spontaneous / diagnosis. Spleen / pathology. Splenic Rupture / diagnosis. Transplantation, Autologous / adverse effects. Transplantation, Autologous / methods

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18081703.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


39. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Leung N, Zeldenrust SR, Buadi FK, Kyle RA, Rajkumar SV, Gertz MA: Serum uric acid: novel prognostic factor in primary systemic amyloidosis. Mayo Clin Proc; 2008 Mar;83(3):297-303
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum uric acid: novel prognostic factor in primary systemic amyloidosis.
  • OBJECTIVE: To determine the prognostic value of serum uric acid (UA) in patients with primary systemic (light chain) amyloidosis (AL).
  • [MeSH-major] Amyloidosis / blood. Uric Acid / blood

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18315995.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Troponin T; 114471-18-0 / Natriuretic Peptide, Brain; 268B43MJ25 / Uric Acid
  •  go-up   go-down


40. Kalajian AH, Waldman M, Knable AL: Nodular primary localized cutaneous amyloidosis after trauma: a case report and discussion of the rate of progression to systemic amyloidosis. J Am Acad Dermatol; 2007 Aug;57(2 Suppl):S26-9
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular primary localized cutaneous amyloidosis after trauma: a case report and discussion of the rate of progression to systemic amyloidosis.
  • Nodular primary localized cutaneous amyloidosis (NPLCA) has been associated with progression to systemic amyloidosis.
  • The reported estimate of 50% progression to systemic amyloidosis has come under scrutiny as recent studies have suggested a significantly lower rate.
  • Still, it is essential to consider systemic amyloidosis after making the diagnosis of NPLCA and to follow up patients longitudinally for possible progression to systemic disease.
  • We present a case of a 24-year-old woman with NPLCA with onset after traumatic injury, review the literature, and discuss the proposed rate of progression of NPLCA to systemic amyloidosis.
  • [MeSH-major] Amyloidosis / pathology. Chin / injuries. Skin Diseases / pathology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637365.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Cho SB, Park JS, Kim HO, Chung KY: Scleroderma-like manifestation in a patient with primary systemic amyloidosis: response to high-dose intravenous immunoglobulin and plasma exchange. Yonsei Med J; 2006 Oct 31;47(5):737-40
MedlinePlus Health Information. consumer health - Scleroderma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scleroderma-like manifestation in a patient with primary systemic amyloidosis: response to high-dose intravenous immunoglobulin and plasma exchange.
  • A 54-year-old Korean male with scleroderma-like manifestation of primary systemic amyloidosis presented with firm cutaneous induration of face and distal extremities, subcutaneous induration of the trunk and proximal extremities, limited range of motion in all joints, hoarseness, and dysphagia.
  • To summarize, hdIVIg and TPE combination therapy may be used as a safe first-line treatment for patients with primary systemic amyloidosis presenting with symptomatic monoclonal gammopathy.
  • [MeSH-major] Amyloidosis / complications. Immunoglobulins, Intravenous / therapeutic use. Plasma Exchange. Scleroderma, Systemic / therapy

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Scleroderma.
  • Genetic Alliance. consumer health - Systemic Scleroderma.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2000 Aug;43(2 Pt 2):403-8 [10901735.001]
  • [Cites] Ther Apher. 2002 Feb;6(1):45-52 [11886576.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4276-82 [12036853.001]
  • [Cites] Eur Neurol. 2003;50(3):172-5 [14530624.001]
  • [Cites] Medicine (Baltimore). 1975 Jul;54(4):271-99 [1152671.001]
  • [Cites] Mayo Clin Proc. 1983 Oct;58(10):665-83 [6353084.001]
  • [Cites] Hepatogastroenterology. 1994 Apr;41(2):204-5 [8056416.001]
  • [Cites] J Intern Med. 1992 Dec;232(6):511-2 [1474353.001]
  • [Cites] Br J Dermatol. 1993 May;128(5):542-5 [8504046.001]
  • [Cites] Semin Arthritis Rheum. 1994 Oct;24(2):124-38 [7839154.001]
  • [Cites] J Intern Med. 1995 Feb;237(2):143-9 [7852916.001]
  • [Cites] Semin Hematol. 1995 Jan;32(1):60-79 [7878479.001]
  • [Cites] Am J Dermatopathol. 1998 Oct;20(5):438-42 [9790101.001]
  • [Cites] Am J Med. 1987 Jun;82(6):1182-90 [3605135.001]
  • (PMID = 17066519.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous
  • [Other-IDs] NLM/ PMC2687761
  •  go-up   go-down


42. Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, Di Palma AM, Gallo M, Rosati A, Tosi PL, Salvadori M, Immunopathology Group of the Italian Society of Nephrology: Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant; 2008 Mar;23(3):941-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
  • BACKGROUND: Few data are available from large population-based studies on survival and renal outcome of patients with renal involvement and different types of systemic amyloidosis.
  • METHODS: Two hundred and ninety of over 373 patients affected from systemic amyloidosis with renal involvement diagnosed in Italy between January 1995 and December 2000 were followed from diagnosis to death or until the last available clinical control.
  • Clinical and laboratory information was collected according to the different types of amyloidosis using a specific form which included renal function with 24 h proteinuria at diagnosis and at the end of follow-up, the type and the date of onset of dialysis and the kind of treatment they underwent.
  • RESULTS: The median time of follow-up was 24 months in primary (AL) amyloidosis (range: 1-88 months), 16 months in AL with associated multiple myeloma (MM + AL: range 1-76 months), 30 months in reactive (AA) amyloidosis (range: 1-99 months) and 52 months in patients with familial forms (AF: range 14-82 months).
  • At the time being, renal transplantation and ASCT are still rare therapeutic options for renal patients affected from systemic amyloidosis.
  • [MeSH-major] Amyloidosis / complications. Amyloidosis / mortality. Kidney Diseases / etiology. Kidney Diseases / mortality

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17951308.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


43. Li J, Zhao Y, Zeng LJ, Su C, Wang HH: [The effects and safety of bortezomib combined with dexamethasone in the treatment of primary systemic amyloidosis]. Zhonghua Nei Ke Za Zhi; 2009 Sep;48(9):741-4
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The effects and safety of bortezomib combined with dexamethasone in the treatment of primary systemic amyloidosis].
  • OBJECTIVE: To evaluate the effects and safety of the regimen of bortezomib combined with dexamethasone (VD) in the treatment of primary systemic (AL) amyloidosis.
  • METHODS: Five newly diagnosed AL amyloidosis patients confirmed by renal biopsy with a median of 3 organs involved (3 to 5 organs) were treated by VD regimen for 3 (1-4) cycles.
  • CONCLUSION: VD regimen might be an efficient, rapid effective and safe regimen in the treatment of AL amyloidosis.
  • [MeSH-major] Amyloidosis / drug therapy. Boronic Acids / therapeutic use. Dexamethasone / therapeutic use. Pyrazines / therapeutic use

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079210.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Drug Combinations; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


44. Stammler F: [Haemorrhagic diathesis as an early symptom of systemic amyloidosis]. Dtsch Med Wochenschr; 2006 Jan 5;131(1-2):17-21
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Haemorrhagic diathesis as an early symptom of systemic amyloidosis].
  • DIAGNOSIS, TREATMENT AND COURSE: These findings indicated the diagnosis of primary AL amyloidosis associated with a gammopathy of unknown significance and a secondary AA amyloidosis in the presence of chronic Bechterev s disease.
  • CONCLUSION: In a case of bleeding of unknown cause systemic amyloidosis should be considered in the differential diagnosis.
  • A tendency towards bleeding, as in this patient, may be the first sign of amyloidosis, which ist often diagnosed quite late in the course of the disease.
  • [MeSH-major] Amyloidosis / diagnosis. Hemorrhagic Disorders / etiology. Spondylitis, Ankylosing / complications

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Ankylosing Spondylitis.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dtsch Med Wochenschr. 2006 Jan 27;131(4):174
  • (PMID = 16374737.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glucocorticoids; Q41OR9510P / Melphalan; VB0R961HZT / Prednisone
  •  go-up   go-down


45. Wittich CM, Neben-Wittich MA, Mueller PS, Gertz MA, Edwards WD: Deposition of amyloid proteins in the epicardial coronary arteries of 58 patients with primary systemic amyloidosis. Cardiovasc Pathol; 2007 Mar-Apr;16(2):75-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deposition of amyloid proteins in the epicardial coronary arteries of 58 patients with primary systemic amyloidosis.
  • INTRODUCTION: We sought to determine the distribution and the effect of amyloid on epicardial coronary arteries in patients with primary cardiac amyloidosis.
  • METHODS: We reviewed pathologic specimens taken after autopsy or cardiac transplantation from 58 patients with primary cardiac amyloidosis.
  • Patients with obstruction of the vasa vasorum were significantly more likely to have obstructive intramural coronary amyloidosis than patients without vasa vasorum obstruction (P=.002).
  • CONCLUSIONS: The epicardial coronary arteries of patients with primary cardiac amyloidosis had extensive amyloid deposition.
  • Obstruction of the vasa vasorum was associated with obstructive intramural coronary amyloidosis.
  • [MeSH-major] Amyloid / metabolism. Amyloidosis / metabolism. Coronary Vessels / metabolism. Pericardium / metabolism

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317539.001).
  • [ISSN] 1054-8807
  • [Journal-full-title] Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology
  • [ISO-abbreviation] Cardiovasc. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid
  •  go-up   go-down


46. Bistolfi F: Localized amyloidosis and Alzheimer's disease: the rationale for weekly long-term low dose amyloid-based fractionated radiotherapy. Neuroradiol J; 2008 Dec 17;21(5):683-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized amyloidosis and Alzheimer's disease: the rationale for weekly long-term low dose amyloid-based fractionated radiotherapy.
  • Amyloidosis, a plasma cell dyschrasia, is characterized by accumulation in the intercellular spaces of fibrillar proteins with a typical beta-sheet pattern.
  • Vascular-cerebral amyloidosis is the hallmark of Alzheimer's disease and spongiform encephalopathy (Creutzfeldt-Jacob and the like).
  • Current treatment of primary systemic amyloidosis is neither free from complications nor - in some presentations - a mortality rate.
  • Localized tracheo-bronchial amyloidosis (TBA) has been successfully treated with high energy beams of radiation (20 Gy in 10×200 cGy in two weeks).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24257012.001).
  • [ISSN] 1971-4009
  • [Journal-full-title] The neuroradiology journal
  • [ISO-abbreviation] Neuroradiol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, Kumar SK, Clark R, Kyle RA, Litzow MR, Inwards DJ, Ansell SM, Micallef IM, Porrata LF, Elliott MA, Johnston PB, Greipp PR, Witzig TE, Zeldenrust SR, Russell SJ, Gastineau D, Gertz MA: Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood; 2006 Apr 15;107(8):3378-83
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
  • The immunoglobulin free light chain (FLC) is the precursor protein of amyloid in primary systemic amyloidosis (AL).

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]
  • [Cites] Blood. 1998 May 15;91(10):3662-70 [9573002.001]
  • [Cites] Am J Hematol. 2005 Aug;79(4):319-28 [16044444.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(7):597-600 [16044137.001]
  • [Cites] Clin Chem. 2001 Apr;47(4):673-80 [11274017.001]
  • [Cites] Clin Chem. 2002 Sep;48(9):1437-44 [12194920.001]
  • [Cites] Am J Clin Pathol. 2003 Feb;119(2):274-8 [12579999.001]
  • [Cites] Lancet. 2003 May 24;361(9371):1787-9 [12781539.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):78-84 [12823348.001]
  • [Cites] N Engl J Med. 2003 Aug 7;349(6):583-96 [12904524.001]
  • [Cites] Ann Intern Med. 2004 Jan 20;140(2):85-93 [14734330.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2936-8 [15070667.001]
  • [Cites] Circ Res. 2004 Apr 30;94(8):1008-10 [15044325.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1881-7 [15044258.001]
  • [Cites] Blood. 1991 Jan 15;77(2):257-62 [1985692.001]
  • [Cites] Semin Hematol. 1995 Jan;32(1):45-59 [7878478.001]
  • [Cites] N Engl J Med. 1996 Jul 11;335(2):91-7 [8649495.001]
  • [Cites] Bone Marrow Transplant. 2004 Dec;34(12):1025-31 [15516945.001]
  • (PMID = 16397135.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA62 242
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid; 0 / Biomarkers; 0 / Immunoglobulin Light Chains
  • [Other-IDs] NLM/ PMC1895763
  •  go-up   go-down


48. Leung N, Griffin MD, Dispenzieri A, Haugen EN, Gloor JM, Schwab TR, Textor SC, Lacy MQ, Litzow MR, Cosio FG, Larson TS, Gertz MA, Stegall MD: Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am J Transplant; 2005 Jul;5(7):1660-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement.
  • Primary systemic amyloidosis (AL) is characterized by multiorgan deposition of monoclonal immunoglobulin light chain.
  • One patient, who has thus far elected not to undergo SCT, has proteinuria and histologic evidence of recurrent renal amyloidosis.
  • [MeSH-major] Amyloidosis / surgery. Kidney Diseases / surgery. Kidney Transplantation. Living Donors. Stem Cell Transplantation


49. Maurer MS, Raina A, Hesdorffer C, Bijou R, Colombo P, Deng M, Drusin R, Haythe J, Horn E, Lee SH, Marboe C, Naka Y, Schulman L, Scully B, Shapiro P, Prager K, Radhakrishnan J, Restaino S, Mancini D: Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation; 2007 Mar 15;83(5):539-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure.
  • BACKGROUND: Systemic amyloidosis complicated by heart failure is associated with high cardiovascular morbidity and mortality.
  • Heart transplantation for patients with systemic amyloidosis is controversial due to recurrence of disease in the transplanted organ or progression of disease in other organs.
  • METHODS: All patients with systemic amyloidosis and heart failure referred for heart transplant evaluation from 1997 to 2004 were included in this retrospective cohort analysis.
  • An interdisciplinary protocol for cardiac transplantation using extended-donor criteria organs, followed in 6 months by either high-dose chemotherapy and stem cell transplantation for patients with primary (AL) or by orthotopic liver transplantation for familial (ATTR) amyloidosis, was developed.
  • RESULTS: A total of 25 patients with systemic amyloidosis and heart failure were included in the study; 12 patients received heart transplants.
  • [MeSH-major] Amyloidosis / surgery. Heart Failure / surgery. Heart Transplantation / methods. Tissue Donors
  • [MeSH-minor] Amyloidosis, Familial / complications. Amyloidosis, Familial / surgery. Creatinine / blood. Female. Humans. Male. Middle Aged. Patient Selection. Stem Cell Transplantation. Survival Analysis. Treatment Outcome


50. Cordier JF: Pulmonary amyloidosis in hematological disorders. Semin Respir Crit Care Med; 2005 Oct;26(5):502-13
MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary amyloidosis in hematological disorders.
  • Amyloidosis is defined by tissue deposits of amyloid, a proteic substance with a characteristic spatial structure of beta-sheet fibrils assembled into bundles.
  • Pulmonary amyloidosis may be either part of systemic amyloidosis (primary amyloidosis or associated with myeloma) or organ-limited.
  • Pulmonary interstitial amyloidosis in systemic amyloidosis is rarely symptomatic unless amyloid deposits severely affect gas exchange alveolar structures, thus resulting in serious respiratory impairment.
  • Localized parenchymal involvement may present as nodular amyloidosis or as amyloid deposits in the vicinity of pulmonary lymphomas.
  • Tracheobronchial amyloidosis, which is not associated with evident clonal proliferation, results in airway stenoses necessitating iterative laser treatment.
  • Treatment of systemic amyloidosis aims at reducing the clonal cell populations producing amyloidogenic immunoglobulins, using high-dose chemotherapy followed by autologous stem cell transplantation in carefully selected patients.
  • Its efficiency in treating diffuse pulmonary amyloidosis has not been established.
  • [MeSH-major] Amyloidosis / complications. Hematologic Diseases / complications. Lung Diseases, Interstitial / complications

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16267701.001).
  • [ISSN] 1069-3424
  • [Journal-full-title] Seminars in respiratory and critical care medicine
  • [ISO-abbreviation] Semin Respir Crit Care Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 144
  •  go-up   go-down


51. Ozdemir D, Dagdelen S, Erbas T: Endocrine involvement in systemic amyloidosis. Endocr Pract; 2010 Nov-Dec;16(6):1056-63
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine involvement in systemic amyloidosis.
  • OBJECTIVE: To present an overview of the published data on endocrine involvement and endocrine dysfunction in patients with systemic amyloidosis.
  • METHODS: We conducted a review of the medical literature using MEDLINE data sources, including clinical trials, in vitro studies, and case reports on pituitary, thyroid, parathyroid, pancreatic, adrenal, and gonadal involvement in systemic amyloidosis.
  • RESULTS: Reports of endocrine involvement in systemic amyloidosis seem to consist primarily of small-samplesize clinical trials or case reports, probably because of the rarity of the disease itself.
  • Systemic amyloidosis mainly involves and causes functional impairment in the thyroid and testes in the endocrine system.
  • Amyloid deposition commonly seen in the pituitary gland and the pancreas of patients with Alzheimer disease and type 2 diabetes mellitus, respectively, is generally classified as local amyloidosis and should not be confused with systemic involvement.
  • Additionally, detection of amyloid deposition in the thyroid and testes may have a diagnostic role in patients with suspected systemic or renal amyloidosis.
  • CONCLUSION: Published data suggest that systemic amyloidosis frequently involves the endocrine system, and endocrine dysfunction seems to be not as rare as previously thought.
  • Involvement of pituitary, parathyroid, and pancreatic sites in systemic amyloidosis still remains to be clarified.
  • Further studies with larger sample sizes are needed for complete characterization of the effect of systemic amyloidosis on the endocrine system.
  • [MeSH-major] Amyloidosis / physiopathology. Endocrine System / physiopathology

  • Genetic Alliance. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20570812.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


52. Haddad F, Jammal M, Azar H, Mallat S, Nasr F, Dabar G, Ghorra C: [A systemic amyloidosis presenting as a tracheobronchial amyloidosis]. Rev Med Interne; 2010 Apr;31(4):e4-6
MedlinePlus Health Information. consumer health - Tracheal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A systemic amyloidosis presenting as a tracheobronchial amyloidosis].
  • Amyloidosis is a spectrum of disease characterized by the abnormal deposition of fibril amyloid-related proteins in the extracellular space.
  • The most common types of amyloidosis are AL and AA amyloidosis.
  • Amyloidosis is also classified according to the extent of the deposition as systemic or localized.
  • Respiratory amyloidosis is classified as laryngeal, tracheobronchial or parenchymal amyloidosis.
  • Tracheobronchial amyloidosis is classically known as a rare manifestation of the localized disease.
  • A few cases only of systemic amyloidosis presenting as a tracheobronchial disease have been reported.
  • We here report a 26-year-old man who presented with hemoptysis related to a systemic tracheal primary amyloidosis.

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Bronchial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20219273.001).
  • [ISSN] 1768-3122
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


53. Skok P, Knehtl M, Ceranić D, Glumbić I: Splenic rupture in systemic amyloidosis - case presentation and review of the literature. Z Gastroenterol; 2009 Mar;47(3):292-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic rupture in systemic amyloidosis - case presentation and review of the literature.
  • CASE REPORT: The authors present the case of a 52-year-old patient with established systemic amyloidosis.
  • Systemic infiltrative disease, affecting the spleen and other organs, was confirmed posthumously.
  • Described are those forms of amyloidosis which usually represent an unfavorable course of the disease.
  • CONCLUSION: Presented is a patient with a rare form of primary amyloidosis and fatal complication, spleenic rupture.
  • [MeSH-major] Amyloidosis / pathology. Liver Diseases / pathology. Splenic Diseases / pathology. Splenic Rupture / pathology


54. Simmons Z, Specht CS: The neuromuscular manifestations of amyloidosis. J Clin Neuromuscul Dis; 2010 Mar;11(3):145-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The neuromuscular manifestations of amyloidosis.
  • Amyloidosis is a systemic disease that may be acquired or hereditary and which results in the deposition of amyloid fibrils in a variety of tissues causing their progressive dysfunction.
  • Acquired and hereditary amyloidosis can be definitively distinguished from one another only by immunohistochemical staining or molecular genetic testing.
  • Treatment remains a challenge, although chemotherapy and autologous stem cell transplantation offer hope for those with primary systemic amyloidosis, whereas liver transplantation is effective for some forms of hereditary amyloid neuropathy.
  • Much less commonly, myopathy may be a clinically significant manifestation of amyloidosis.
  • [MeSH-major] Amyloidosis / complications. Amyloidosis / diagnosis. Neuromuscular Diseases / complications

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Neuromuscular Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20215989.001).
  • [ISSN] 1537-1611
  • [Journal-full-title] Journal of clinical neuromuscular disease
  • [ISO-abbreviation] J Clin Neuromuscul Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoprotein A-I; 0 / Gelsolin; 0 / Prealbumin
  • [Number-of-references] 92
  •  go-up   go-down


55. Vesole DH, Pérez WS, Akasheh M, Boudreau C, Reece DE, Bredeson CN, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research: High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc; 2006 Jul;81(7):880-8
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.
  • OBJECTIVE: To determine the outcome of high-dose therapy with autologous hematopoietic stem cell transplantation (HSCT) in patients with primary systemic amyloidosis reported to the Center for International Blood and Marrow Transplant Research (CIBMTR).
  • PATIENTS AND METHODS: A total of 107 recipients of autologous HSCT for amyloidosis from 48 transplantation centers were reported to the CIBMTR between 1995 and 2001.
  • RESULTS: Improvement at day 100 was seen in 1 or more amyloidosis-affected sites (bone marrow, kidney, liver, and/or heart) in 28 (36%) of 77 patients; the 1-year responses included complete response (16%), partial response (16%), stable disease (31%), and disease progression (10%).
  • [MeSH-major] Amyloidosis / therapy. Antineoplastic Agents, Alkylating / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Kidney / pathology. Liver / pathology. Melphalan / administration & dosage. Myocardium / pathology

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Mayo Clin Proc. 2006 Jul;81(7):874-6 [16835965.001]
  • (PMID = 16835967.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  •  go-up   go-down


56. Paula JS, Paula SA, Cruz AA, Chahud F: Superior oblique muscle amyloidosis mimicking myositis. Ophthal Plast Reconstr Surg; 2008 Jan-Feb;24(1):77-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superior oblique muscle amyloidosis mimicking myositis.
  • Systemic examination revealed erythematous papules on his trunk and pulmonary infiltrates.
  • A comprehensive systemic investigation failed to show any disease that could explain the amyloid deposits.
  • The patient was then diagnosed as having primary systemic amyloidosis.
  • [MeSH-major] Amyloidosis / diagnosis. Myositis / diagnosis. Oculomotor Muscles / pathology

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Myositis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Myositis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18209659.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Nardi M, Vizzardi E, Farina D, D'Aloia A, Zanini G, Chiari E, Dei Cas L: A giant interatrial mass: an unusual presentation of primary amyloidosis. Kardiol Pol; 2009 Aug;67(8):922-3
MedlinePlus Health Information. consumer health - Cardiomyopathy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A giant interatrial mass: an unusual presentation of primary amyloidosis.
  • We report a patient with primary systemic amyloidosis who had a very unusual form of clinical and instrumental presentation.
  • [MeSH-major] Amyloidosis / ultrasonography. Cardiomyopathies / ultrasonography. Heart Atria / ultrasonography

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19784893.001).
  • [ISSN] 0022-9032
  • [Journal-full-title] Kardiologia polska
  • [ISO-abbreviation] Kardiol Pol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


58. Leung N, Dispenzieri A, Fervenza FC, Lacy MQ, Villicana R, Cavalcante JL, Gertz MA: Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. Am J Kidney Dis; 2005 Aug;46(2):270-7
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
  • BACKGROUND: Primary systemic (AL) amyloidosis is a rare plasma cell disorder characterized by soft-tissue deposition of monoclonal light chain fragments.
  • METHODS: All patients with AL amyloidosis who underwent autologous stem cell transplantation between 1996 and December 2002 were selected for study.
  • CONCLUSION: Currently, high-dose melphalan followed by stem cell transplantation is the most effective treatment for AL amyloidosis for those who are eligible.
  • [MeSH-major] Amyloidosis / therapy. Melphalan / therapeutic use. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112045.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q41OR9510P / Melphalan
  • [Number-of-references] 35
  •  go-up   go-down


59. Mhaskar R, Kumar A, Behera M, Kharfan-Dabaja MA, Djulbegovic B: Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biol Blood Marrow Transplant; 2009 Aug;15(8):893-902
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review.
  • Significant uncertainty exists regarding the efficacy of high-dose chemotherapy and autologous hematopoietic cell transplantation (AHCT) for the treatment of patients with primary systemic (AL) amyloidosis.
  • We performed a systematic review and meta-analysis to evaluate the efficacy of AHCT versus conventional chemotherapy (CC) in patients with AL amyloidosis using methodology recommended by the Cochrane Collaboration.
  • Our findings indicate that AHCT does not appear to be superior to CC in improving OS in patients with AL amyloidosis.
  • But the quality of our evidence is low, indicating a need for well-designed and adequately powered RCTs to better address the role of AHCT in AL amyloidosis.
  • [MeSH-major] Amyloidosis / therapy. Antineoplastic Agents / administration & dosage. Hematopoietic Stem Cell Transplantation / methods

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Biol Blood Marrow Transplant. 2010 Jan;16(1):138-40; author reply 140-1 [19761864.001]
  • (PMID = 19589478.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 37
  •  go-up   go-down


60. Sainz-Esteban A, Saornil-Alvarez MA, Méndez-Díaz MC, Blanco-Mateos G: [Primary localized conjunctival amyloidosis: two case reports]. Arch Soc Esp Oftalmol; 2005 Jan;80(1):49-52
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary localized conjunctival amyloidosis: two case reports].
  • CONCLUSIONS: Primary localized conjunctival amyloidosis is a rare disease.
  • Diagnosis consists of biopsy in order to detect amyloid material in the conjunctival tissue together with a systemic evaluation in order to rule out the presence of primary systemic amyloidosis.
  • [MeSH-major] Amyloidosis / diagnosis. Conjunctival Diseases / diagnosis

  • Genetic Alliance. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692895.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


61. Palladini G, Kyle RA, Larson DR, Therneau TM, Merlini G, Gertz MA: Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis. Amyloid; 2005 Jun;12(2):120-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis.
  • BACKGROUND: Early diagnosis and supportive therapy are important in primary systemic amyloidosis (AL).
  • METHODS: All the patients diagnosed with AL between 1988 and 1998 at Mayo Clinic or in any of the centers of the Italian Amyloidosis Study Group were included.
  • In the Italian cohort, dominant kidney involvement was more frequent (49.3% vs. 27.8%, P<0.001), while in the Mayo group more patients had dominant cardiac amyloidosis (37.4% vs. 27.8%, P=0.03).
  • [MeSH-major] Amyloidosis / therapy

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16011989.001).
  • [ISSN] 1350-6129
  • [Journal-full-title] Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • [ISO-abbreviation] Amyloid
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-62242
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


62. Gertz MA, Leung N, Lacy MQ, Dispenzieri A: Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement. Kidney Int; 2005 Oct;68(4):1464-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement.
  • BACKGROUND: High-dose chemotherapy and stem cell transplantation are being applied increasingly to the treatment of selected patients with multiple myeloma or primary systemic amyloidosis.
  • [MeSH-major] Amyloidosis / therapy. Hematopoietic Stem Cell Transplantation. Multiple Myeloma / therapy. Myeloablative Agonists / therapeutic use. Nephrotic Syndrome / therapy

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16164623.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists
  • [Number-of-references] 51
  •  go-up   go-down


63. Boldueva SA, Samokhvalova MV, Bogdanova EV, Solov'eva TS: [Primary systemic amyloidosis with involvement of the heart and coronary arteries]. Kardiologiia; 2010;50(6):92-4
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary systemic amyloidosis with involvement of the heart and coronary arteries].
  • [MeSH-major] Amyloidosis

  • Genetic Alliance. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20659036.001).
  • [ISSN] 0022-9040
  • [Journal-full-title] Kardiologiia
  • [ISO-abbreviation] Kardiologiia
  • [Language] rus
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Amyloidogenic Proteins; 0 / Anti-Arrhythmia Agents; 0 / Anticoagulants; 0 / Diuretics; 0 / Platelet Aggregation Inhibitors
  •  go-up   go-down


64. Esteve V, Almirall J, Ponz E, García N, Ribera L, Larrosa M, Andreu X, García M: [Renal involvement in amyloidosis. Clinical outcomes, evolution and survival]. Nefrologia; 2006;26(2):212-7
MedlinePlus Health Information. consumer health - Kidney Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal involvement in amyloidosis. Clinical outcomes, evolution and survival].
  • BACKGROUND: Systemic amyloidosis is a disease resulting from extracellular deposition of fibrillar protein in various organs.
  • Main systemic amyloidosis are: primary (AL) and Secondary (AA).
  • In the last decade there has been a change in the aetiology of AA amyloidosis.
  • OBJECTIVES: To analyse the incidence of AL and AA amyloidosis in our current population as well as the aetiology of AA amyloidosis.
  • PATIENTS AND METHODS: We performed a descriptive analysis of all cases of amyloidosis diagnosed from 1992 to 2004 in our hospital.
  • Types: 55 AA (72%), 21 AL (28%) systemic amyloidosis.
  • CONCLUSIONS: Although amyloidosis has a low incidence in our population, the kidney is usually involved.
  • Rheumatological disorders are the principal aetiology of AA amyloidosis.
  • [MeSH-major] Amyloidosis / complications. Kidney Diseases / etiology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16808259.001).
  • [ISSN] 0211-6995
  • [Journal-full-title] Nefrología : publicación oficial de la Sociedad Española Nefrologia
  • [ISO-abbreviation] Nefrologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


65. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Leung N, Gastineau DA: Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL). Bone Marrow Transplant; 2007 Nov;40(10):989-93
Hazardous Substances Data Bank. Filgrastim .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL).
  • Stem cell transplantation is increasingly used in the management of immunoglobulin light-chain amyloidosis (AL).
  • [MeSH-major] Amyloidosis / therapy. Graft Survival. Granulocyte Colony-Stimulating Factor / therapeutic use. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846598.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


66. Petre RE, Quaile MP, Wendt K, Houser SR, Wald J, Goldman BI, Margulies KB: Regionally heterogeneous tissue mechanics in cardiac amyloidosis. Amyloid; 2005 Dec;12(4):246-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regionally heterogeneous tissue mechanics in cardiac amyloidosis.
  • OBJECTIVE: The goal of this study was to examine in vitro tissue stiffness and contractile performance in myocardial amyloidosis.
  • BACKGROUND: Primary systemic amyloidosis involves the deposition of amyloid protein in mesodermal tissues including the heart.
  • Functional assessment of cardiac amyloidosis is usually performed using echocardiography.
  • METHODS: At the time of heart transplantation, isolated myocardial trabeculae were dissected from the right ventricle of a patient with primary systemic amyloidosis.
  • [MeSH-major] Amyloidosis / physiopathology. Heart / physiopathology. Isometric Contraction. Myocardial Contraction. Myocardial Ischemia / physiopathology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399650.001).
  • [ISSN] 1350-6129
  • [Journal-full-title] Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • [ISO-abbreviation] Amyloid
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG17022
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Ozyigit LP, Kiyan E, Okumus G, Yilmazbayhan D: Isolated laryngo-tracheal amyloidosis presenting as a refractory asthma and longstanding hoarseness. J Asthma; 2009 Apr;46(3):314-7
MedlinePlus Health Information. consumer health - Tracheal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated laryngo-tracheal amyloidosis presenting as a refractory asthma and longstanding hoarseness.
  • Respiratory tract amyloidosis is characterized by deposition of amyloid fibril protein at any site along the respiratory tract ranging from the larynx to the pulmonary parenchyma.
  • Usually, it is not associated with primary systemic amyloidosis.
  • We report a case with isolated laryngotracheal amyloidosis, which is relatively a rare condition, together with a history of refractory asthma accompanied with longstanding hoarseness.
  • [MeSH-major] Amyloidosis / radiography. Asthma / complications. Hoarseness / complications. Laryngeal Diseases / radiography. Tracheal Diseases / radiography

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Asthma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19373642.001).
  • [ISSN] 1532-4303
  • [Journal-full-title] The Journal of asthma : official journal of the Association for the Care of Asthma
  • [ISO-abbreviation] J Asthma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Elad S, Czerninski R, Fischman S, Keshet N, Drucker S, Davidovich T, Goldschmidt N: Exceptional oral manifestations of amyloid light chain protein (AL) systemic amyloidosis. Amyloid; 2010 Mar;17(1):27-31
MedlinePlus Health Information. consumer health - Mouth Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exceptional oral manifestations of amyloid light chain protein (AL) systemic amyloidosis.
  • Oral amyloidosis is usually presented in the tongue and is often associated with multiple myeloma.
  • We present three patients with unusual oral manifestations of primary amyloidosis, which to the best of our knowledge have not been previously published.
  • Since these oral manifestations can contribute to the diagnosis of systemic amyloidosis, clinicians should be made aware of them.
  • [MeSH-major] Amyloid / metabolism. Amyloidosis / diagnosis. Immunoglobulin Light Chains / metabolism. Mouth Diseases / diagnosis

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20146645.001).
  • [ISSN] 1744-2818
  • [Journal-full-title] Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • [ISO-abbreviation] Amyloid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amyloid; 0 / Immunoglobulin Light Chains
  •  go-up   go-down


69. Turkmen K, Anil M, Solak Y, Atalay H, Esen H, Tonbul HZ: A hepatitis C-positive patient with new onset of nephrotic syndrome and systemic amyloidosis secondary to common variable immunodeficiency. Ann Saudi Med; 2010 Sep-Oct;30(5):401-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A hepatitis C-positive patient with new onset of nephrotic syndrome and systemic amyloidosis secondary to common variable immunodeficiency.
  • Common variable immunodeficiency (CVID) is a heterogenous group of predominantly antibody-deficiency disorders that make up the greatest proportion of patients with symptomatic primary hypogammaglobulinemia.
  • The rare coincidence of amyloidosis and hypogammaglobulinemia has been reported previously.
  • We report a HCV-positive patient with a new onset of nephrotic syndrome and systemic amyloidosis secondary to CVID.
  • Duodenal biopsy revealed AA-type amyloidosis with potassium permanganate and Congo red staining.
  • [MeSH-major] Amyloidosis / etiology. Common Variable Immunodeficiency / complications. Hepatitis C Antibodies / blood. Nephrotic Syndrome / etiology

  • Genetic Alliance. consumer health - C Syndrome.
  • Genetic Alliance. consumer health - Common Variable Immunodeficiency.
  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • Hazardous Substances Data Bank. Losartan .
  • Hazardous Substances Data Bank. CIPROFLOXACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Q J Med. 1993 Jan;86(1):31-42 [8438047.001]
  • [Cites] Clin Exp Immunol. 1995 Oct;102(1):11-6 [7554376.001]
  • [Cites] Clin Immunol. 1999 Jul;92(1):34-48 [10413651.001]
  • [Cites] Yonsei Med J. 2005 Dec 31;46(6):847-50 [16385663.001]
  • [Cites] Dig Dis Sci. 2007 Nov;52(11):2977-83 [17431775.001]
  • [Cites] Medicine (Baltimore). 1985 May;64(3):145-56 [2581110.001]
  • [Cites] Immunol Allergy Clin North Am. 2008 Nov;28(4):691-713, vii [18940570.001]
  • [Cites] Clin Immunol. 1999 Dec;93(3):190-7 [10600329.001]
  • [Cites] Am J Gastroenterol. 2003 Jan;98(1):118-21 [12526946.001]
  • [Cites] N Engl J Med. 1985 Feb 14;312(7):446 [3969103.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):489-502 [18692715.001]
  • (PMID = 20697163.001).
  • [ISSN] 0975-4466
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Anti-Infective Agents; 0 / Hepatitis C Antibodies; 0 / Immunoglobulins, Intravenous; 0 / Immunologic Factors; 5E8K9I0O4U / Ciprofloxacin; JMS50MPO89 / Losartan; L35JN3I7SJ / Ramipril
  • [Other-IDs] NLM/ PMC2941255
  •  go-up   go-down


70. Higeta D, Yokohama A, Osaki Y, Tahara K, Mawatari M, Sekigami T, Koiso H, Saito T, Uchiumi H, Handa H, Karasawa M, Murakami H, Hirato J, Tsukamoto N, Nojima Y: [IgM-lambda multiple myeloma presenting with systemic amyloidosis]. Rinsho Ketsueki; 2009 Dec;50(12):1711-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [IgM-lambda multiple myeloma presenting with systemic amyloidosis].
  • These findings led to a diagnosis of IgM multiple myeloma with systemic amyloidosis.
  • [MeSH-major] Amyloidosis / etiology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunoglobulin M. Multiple Myeloma / complications

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20068279.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Immunoglobulin M; 0 / Pyrazines; 5J49Q6B70F / Vincristine; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; VAD protocol
  •  go-up   go-down


71. Carvalho LO, Calabrese Kda S, da Costa SC, Mendes VG, da Silva AP, Barros AC, Melo Sde A, Abreu-Silva AL: Leishmania (Leishmania) amazonensis: experimental cutaneous leishmaniasis associated with systemic amyloidosis in mice. Exp Parasitol; 2008 Sep;120(1):123-5
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leishmania (Leishmania) amazonensis: experimental cutaneous leishmaniasis associated with systemic amyloidosis in mice.
  • Histopathologically, the primary lesion showed an extensive liquefactive necrosis and inflammatory infiltrate, mainly consisting of macrophages filled with amastigotes, and rare lymphocytes.
  • Additionally, C57BL/6 had accentuated amyloidosis in both ovarian cortical and medullar region and inflammatory infiltrates in the pancreas and adrenal gland.
  • [MeSH-major] Amyloidosis / complications. Leishmania mexicana. Leishmaniasis, Cutaneous / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18601926.001).
  • [ISSN] 1090-2449
  • [Journal-full-title] Experimental parasitology
  • [ISO-abbreviation] Exp. Parasitol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


72. Silva D, Sargento L, Varela MG, Brito D, Lopes MG: Behind heart failure syndrome: remember AL amyloidosis. Two case-reports. Rev Port Cardiol; 2010 Nov;29(11):1751-9
MedlinePlus Health Information. consumer health - Heart Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Behind heart failure syndrome: remember AL amyloidosis. Two case-reports.
  • Amyloidosis is a systemic disease that is a consequence of extracellular deposition of insoluble fibrils composed of subunits of low molecular weight (5-25 kD) derived from a variety of plasma proteins.
  • Identification of the amyloidogenic protein determines the type of amyloidosis.
  • In primary systemic amyloidosis (classically called AL amyloidosis), the amyloid protein is composed of light chains resulting from plasma-cell dyscrasia.
  • Cardiac manifestations are the most common clinical presentation of this type of amyloidosis, occurring in 50% of patients.
  • [MeSH-major] Amyloidosis / complications. Heart Failure / etiology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21309362.001).
  • [ISSN] 0870-2551
  • [Journal-full-title] Revista portuguesa de cardiologia : orgão oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology
  • [ISO-abbreviation] Rev Port Cardiol
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


73. Bergesio F, Ciciani AM, Santostefano M, Brugnano R, Manganaro M, Palladini G, Di Palma AM, Gallo M, Tosi PL, Salvadori M, Immunopathology Group, Italian Society of Nephrology: Renal involvement in systemic amyloidosis--an Italian retrospective study on epidemiological and clinical data at diagnosis. Nephrol Dial Transplant; 2007 Jun;22(6):1608-18
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal involvement in systemic amyloidosis--an Italian retrospective study on epidemiological and clinical data at diagnosis.
  • BACKGROUND: Few data are available on epidemiology and clinical picture of renal involvement in different forms of systemic amyloidosis.
  • METHODS: Patients with biopsy-proven systemic amyloidosis diagnosed in Italy between January 1995 and December 2000 were selected from 49 Nephrology and Internal Medicine Units provided they showed signs characteristic of renal involvement.
  • Collected data were matched both with the Italian Registry of Renal Biopsies (IRRB) and the Registry of the Italian Society of Amyloidosis (SIA) in order to approximate the incidence of the disease.
  • RESULTS: Of all patients, 373 were finally selected throughout Italy with an estimated mean incidence of renal amyloidosis of 2.1 per million population (p.m.p.) per year.
  • Of those, 237 were affected from AL (primary) amyloidosis, 104 from AA (secondary) amyloidosis and 6 from AF (heredofamilial) forms.
  • In 26 cases the type of amyloidosis remained undetermined.
  • CONCLUSIONS: Our results point to an increased incidence of renal amyloidosis observed in Italy over the period 1996-2000 with AL as the prevalent type.
  • [MeSH-major] Amyloidosis / diagnosis. Amyloidosis / epidemiology. Kidney Diseases / diagnosis. Kidney Diseases / epidemiology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17395661.001).
  • [ISSN] 0931-0509
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


74. Sakata N, Hoshii Y, Nakamura T, Kiyama M, Arai H, Omoto M, Morimatsu M, Ishihara T: Colocalization of apolipoprotein AI in various kinds of systemic amyloidosis. J Histochem Cytochem; 2005 Feb;53(2):237-42
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colocalization of apolipoprotein AI in various kinds of systemic amyloidosis.
  • We examined colocalization of apoAI in various kinds of systemic amyloidosis in this study.
  • Forty-three of 48 formalin-fixed paraffin-embedded heart specimens with various forms of systemic amyloidosis reacted immunohistochemically with anti-human apoAI antibody.
  • In addition, we observed colocalization of apoAI and murine amyloid A (AA) amyloidosis in human apoAI transgenic mice.
  • This is the first report of colocalization of apoAI with amyloid deposits in various forms of human systemic amyloidosis and murine AA amyloidosis in human apoAI transgenic mice.
  • ApoAI may not always be a major component of amyloid fibrils, even when it is present in systemic amyloid deposits.
  • [MeSH-major] Amyloidosis / metabolism. Apolipoprotein A-I / metabolism

  • Genetic Alliance. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15684336.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoprotein A-I; 0 / Serum Amyloid A Protein
  •  go-up   go-down


75. Chraibi A, Msyah L, Laaribi O, Marrakchi A, Hafidi A: [Amyloid goiter: first sign of systemic amyloidosis]. Ann Endocrinol (Paris); 2009 Mar;70(1):80-2
Hazardous Substances Data Bank. COLCHICINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Amyloid goiter: first sign of systemic amyloidosis].
  • The diagnosis is rarely suggested clinically even in the presence of known amyloidosis.
  • We describe the case of a 45-year-old patient who presented an amyloid goiter as the first manifestation of systemic amyloidosis, probably secondary to bronchiectasis.
  • [MeSH-major] Amyloidosis / diagnosis. Goiter / complications

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18082156.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] Q51BO43MG4 / Thyroxine; SML2Y3J35T / Colchicine
  •  go-up   go-down


76. Finkel KJ, Kolansky DM, Giorgadze T, Thaler E: Amyloid infiltration of the salivary glands in the setting of primary systemic amyloidosis without multiple myeloma. Otolaryngol Head Neck Surg; 2006 Sep;135(3):471-2
Hazardous Substances Data Bank. C.I. DIRECT RED 28 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amyloid infiltration of the salivary glands in the setting of primary systemic amyloidosis without multiple myeloma.
  • [MeSH-major] Amyloidosis / diagnosis. Parotid Diseases / diagnosis. Submandibular Gland Diseases / diagnosis

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949985.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid; 0 / Coloring Agents; 3U05FHG59S / Congo Red
  •  go-up   go-down


77. Mainenti PP, Camera L, Nicotra S, Cantalupo T, Soscia E, Di Vizio D, Insabato G, Salvatore M: Splenic hypoperfusion as a sign of systemic amyloidosis. Abdom Imaging; 2005 Nov-Dec;30(6):768-72
MedlinePlus Health Information. consumer health - Spleen Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic hypoperfusion as a sign of systemic amyloidosis.
  • BACKGROUND: The spleen is frequently involved in systemic amyloidosis; however, the computed tomographic (CT) or magnetic resonance (MR) pattern of splenic amyloidosis is not sufficiently described in the literature.
  • This study evaluated the contrast-enhanced CT and MR findings of the spleen in patients with systemic amyloidosis.
  • Thirty-three patients with amyloidosis were identified, 10 of whom had a CT scan and two of whom had an MR study.
  • The population-based study was composed of 12 patients with histologically proved amyloidosis who underwent contrast-enhanced CT or MR scan of the abdomen.
  • CONCLUSION: The finding of splenic hypoperfusion may be a marker of systemic amyloidosis, which represents a useful clue when clinical findings fail to suggest the proper diagnosis.
  • [MeSH-major] Amyloidosis / diagnosis. Magnetic Resonance Imaging. Spleen / blood supply. Splenic Diseases / diagnosis. Tomography, X-Ray Computed


78. Kazdaghli Lagha E, M'sakni I, Bougrine F, Laabidi B, Ben Ghachem D, Bouziani A: Amyloid goiter: first manifestation of systemic amyloidosis. Eur Ann Otorhinolaryngol Head Neck Dis; 2010 Jun;127(3):108-10
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amyloid goiter: first manifestation of systemic amyloidosis.
  • Amyloidosis is an abnormal extracellular deposit, which can occur in several tissues.
  • In systemic amyloidosis, all the organs can be infiltrated, but amyloid goiter as the initial manifestation of systemic amyloidosis is an exceedingly rare condition.
  • We report a rare case of a patient who presented an amyloid goiter as the first manifestation of systemic amyloidosis.
  • Amyloid goiter is a rare manifestation of amyloidosis.
  • The prognosis depends on the treatment of the amyloidosis and the underlying chronic disease.
  • [MeSH-major] Amyloidosis / complications. Goiter / etiology

  • Genetic Alliance. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Masson SAS.
  • (PMID = 20822765.001).
  • [ISSN] 1879-730X
  • [Journal-full-title] European annals of otorhinolaryngology, head and neck diseases
  • [ISO-abbreviation] Eur Ann Otorhinolaryngol Head Neck Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Amyloid
  •  go-up   go-down


79. Park JY, Yim HJ, Yoon I, Park SM, Kim JN, Lee HS, Lee SW, Choi JH: [A case of systemic amyloidosis with pancreatic involvement mimicking autoimmune pancreatitis]. Korean J Gastroenterol; 2008 Dec;52(6):399-403
MedlinePlus Health Information. consumer health - Pancreatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of systemic amyloidosis with pancreatic involvement mimicking autoimmune pancreatitis].
  • Systemic amyloidosis is a disorder characterized by extracellular deposition of amyloid in various organs and tissues including the kidney, heart, and liver.
  • Systemic amyloisosis involving pancreas needs to be differentiated from several pancreatic diseases because of diffuse pancreatic enlargement and partial stricture or obstruction of main pancreatic duct.
  • Recently, we experienced a 60-year old man who was suspected as autoimmune pancreatitis or infiltrative disorders on imaging studies, and finally diagnosed as systemic amyloidosis involving pancreas and liver on biopsy examination.
  • [MeSH-major] Amyloidosis / diagnosis. Pancreatic Diseases / diagnosis

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096259.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


80. Ikeda S: [Diagnosis and treatment in systemic amyloidosis]. Rinsho Byori; 2008 Feb;56(2):121-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment in systemic amyloidosis].
  • Systemic amyloidosis is characterized by the involvement of multiple organs and the presence of an amyloid precursor protein in serum.
  • Heart, kidney, gastrointestinal tract and peripheral nerves are commonly affected by amyloid deposition in systemic amyloidosis and histopathological demonstration of amyloid deposits on any of affected organs is the first step leading to the diagnosis of this disease.
  • Amyloidosis had been considered to be an incurable disease but during the past one decade several therapeutic approaches have been employed for the amyloidosis patients with diverse pathogenetic backgrounds: intravenous large dose of melphalan accompanied by autologous peripheral blood stem cell transplantation for AL amyloidosis and liver transplantation for hereditary ATTR type amyloidosis.
  • As a result some amyloidosis patients have been rescued and are now enjoying their own social lives.
  • It is likely that recent advance on the research of amyloidosis has changed the concept of this disease.
  • [MeSH-major] Amyloidosis / diagnosis. Amyloidosis / therapy

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • Hazardous Substances Data Bank. MELPHALAN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404826.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amyloid; 0 / Prealbumin; Q41OR9510P / Melphalan
  • [Number-of-references] 45
  •  go-up   go-down


81. Rapezzi C, Riva L, Quarta CC, Perugini E, Salvi F, Longhi S, Ciliberti P, Pastorelli F, Biagini E, Leone O, Cooke RM, Bacchi-Reggiani L, Ferlini A, Cavo M, Merlini G, Perlini S, Pasquali S, Branzi A: Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid; 2008 Mar;15(1):40-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender-related risk of myocardial involvement in systemic amyloidosis.
  • To investigate associations between gender and myocardial involvement in systemic amyloidosis, we reviewed all patients presenting between 1994 and September 2006 in our institutional network (100 AL and 98 familial transthyretin-related amyloidosis (ATTR) patients, plus 12 elderly men with senile systemic amyloidosis).
  • [MeSH-major] Amyloidosis / complications. Cardiomyopathies / etiology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18266120.001).
  • [ISSN] 1350-6129
  • [Journal-full-title] Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • [ISO-abbreviation] Amyloid
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones
  •  go-up   go-down


82. Nishi H, Abe A, Kita A, Toki T, Noda N, Tsuchihashi D, Abe T, Umezu M, Yokozaki H, Fukagawa M: Cerebral venous thrombosis in adult nephrotic syndrome due to systemic amyloidosis. Clin Nephrol; 2006 Jan;65(1):61-4
MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral venous thrombosis in adult nephrotic syndrome due to systemic amyloidosis.
  • We report a 79-year-old female with nephrotic syndrome due to systemic amyloidosis who suddenly altered mental status during her hospitalization.
  • [MeSH-major] Amyloidosis / complications. Intracranial Thrombosis / etiology. Nephrotic Syndrome / complications. Venous Thrombosis / etiology

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16429845.001).
  • [ISSN] 0301-0430
  • [Journal-full-title] Clinical nephrology
  • [ISO-abbreviation] Clin. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


83. Vezali E, Elefsiniotis I, Tsioufis C, Kallikazaros I: Unusual initial presentation of primary systemic (AL) amyloidosis with severe cardiomyopathy and fatal outcome. Hellenic J Cardiol; 2006 Nov-Dec;47(6):381-5
MedlinePlus Health Information. consumer health - Cardiomyopathy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual initial presentation of primary systemic (AL) amyloidosis with severe cardiomyopathy and fatal outcome.
  • Primary (AL) amyloidosis is the most common form of systemic amyloidosis seen in current clinical practice.
  • We describe a patient in whom asymptomatic hepatomegaly, cardiomegaly, hyperlipidaemia and elevated serum alkaline phosphatase level were found during routine examination; the final diagnosis was primary systemic AL amyloidosis with severe cardiomyopathy, resulting in a fatal outcome within eight months from the diagnosis.
  • [MeSH-major] Amyloidosis / pathology. Cardiomyopathies / pathology

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17243512.001).
  • [ISSN] 1109-9666
  • [Journal-full-title] Hellenic journal of cardiology : HJC = Hellēnikē kardiologikē epitheōrēsē
  • [ISO-abbreviation] Hellenic J Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


84. Niemczyk R, Brydak-Godowska J, Kecik D, Wagner T, Lewandowski P, Kecik M, Zygier D, Ołdakowska-Jedynak U: Vitreous amyloidosis in two sisters as the indication of transthyretin-related familial form of systemic amyloidosis among liver transplantation candidates. Transplant Proc; 2009 Oct;41(8):3085-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitreous amyloidosis in two sisters as the indication of transthyretin-related familial form of systemic amyloidosis among liver transplantation candidates.
  • Vitreous amyloidosis, a rare condition characteristic of the familial form of systemic amyloidosis with polyneuropathy, is caused by a mutation in the transthyretin (TTR) gene.
  • Herein we have presented 2 sisters with involvement of the vitreous body, which prompted a subsequent diagnosis of the TTR-related, familial form of systemic amyloidosis.


85. Westermark P, Davey E, Lindbom K, Enqvist S: Subcutaneous fat tissue for diagnosis and studies of systemic amyloidosis. Acta Histochem; 2006;108(3):209-13
Hazardous Substances Data Bank. C.I. DIRECT RED 28 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous fat tissue for diagnosis and studies of systemic amyloidosis.
  • The systemic amyloidoses comprise a biochemically heterogeneous group of potentially lethal disorders.
  • Subcutaneous fat biopsy is a simple and safe method to obtain a diagnosis of systemic amyloidosis and the material can be used for exact determination of amyloid type.
  • [MeSH-major] Adipose Tissue / pathology. Amyloid / metabolism. Amyloidosis / diagnosis. Subcutaneous Tissue / pathology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16714055.001).
  • [ISSN] 0065-1281
  • [Journal-full-title] Acta histochemica
  • [ISO-abbreviation] Acta Histochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Amyloid; 0 / Coloring Agents; 3U05FHG59S / Congo Red
  •  go-up   go-down


86. Hukkanen RR, Liggitt HD, Anderson DM, Kelley ST: Detection of systemic amyloidosis in the pig-tailed macaque (Macaca nemestrina). Comp Med; 2006 Apr;56(2):119-27
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of systemic amyloidosis in the pig-tailed macaque (Macaca nemestrina).
  • Secondary amyloidosis is a progressive systemic disease for which there is no reliable diagnostic assay, preventive measure, or treatment.
  • In an attempt to elucidate an antemortem diagnosis, 30 female pig-tailed macaques (Macaca nemestrina) at the Washington National Primate Research Center were surveyed for amyloidosis.
  • Twelve tests were evaluated for detection of amyloidosis; the diagnostic value of each was determined through comparison of histologically positive and histologically negative animals.
  • In the absence of known infection or trauma, an amyloidotic serologic profile and radiologic hepatomegaly are consistent with systemic amyloidosis in M. nemestrina.
  • [MeSH-major] Amyloidosis / veterinary. Liver Diseases / veterinary. Macaca nemestrina. Monkey Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639979.001).
  • [ISSN] 1532-0820
  • [Journal-full-title] Comparative medicine
  • [ISO-abbreviation] Comp. Med.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR00166; United States / NCRR NIH HHS / RR / RR07019-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Serum Albumin; 0 / Serum Amyloid A Protein; EC 2.3.2.2 / gamma-Glutamyltransferase; EC 2.6.1.1 / Aspartate Aminotransferases
  •  go-up   go-down


87. Alvarez-Ruiz SB, Pérez-Gala S, Aragüés M, Fraga J, García-Díez A: Unusual clinical presentation of amyloidosis: bilateral stenosis of the external auditory canal, hoarseness and a rapid course of cutaneous lesions. Int J Dermatol; 2007 May;46(5):503-4
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual clinical presentation of amyloidosis: bilateral stenosis of the external auditory canal, hoarseness and a rapid course of cutaneous lesions.
  • We report a patient with multiple myeloma associated with primary systemic amyloidosis who had a rapid evolution and a very unusual form of presentation.
  • The association of amyloidosis in patients with multiple myeloma is 15%, and clinically evident mucocutaneous involvement occurs in up to 40% of patients.
  • [MeSH-major] Amyloidosis / complications. Ear Canal / abnormalities. Hoarseness / etiology. Skin Diseases / etiology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472683.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Cheng AS, Banning AP, Mitchell AR, Neubauer S, Selvanayagam JB: Cardiac changes in systemic amyloidosis: visualisation by magnetic resonance imaging. Int J Cardiol; 2006 Oct 26;113(1):E21-3
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac changes in systemic amyloidosis: visualisation by magnetic resonance imaging.
  • Cardiac involvement is a significant cause of morbidity and mortality in patients with amyloidosis.
  • This case provides a striking demonstration of the characteristic features of cardiac amyloidosis by cardiovascular magnetic resonance imaging - impaired biventricular systolic function, thickened atrioventricular valves, bi-atrial enlargement, increased atrial septal thickness and left ventricular mass, pleural and pericardial effusions, and the most impressive finding of widespread subendocardial hyperenhancement of both ventricles, as well as the inter-atrial and inter-ventricular septa, representing infiltration with amyloid protein.
  • Cardiac involvement with systemic amyloidosis was suspected and confirmed on biopsy.
  • Cardiovascular magnetic resonance imaging should be considered early in the diagnostic work-up of suspected cardiac amyloidosis.
  • [MeSH-major] Amyloidosis / diagnosis. Magnetic Resonance Imaging. Myocardium / pathology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17049635.001).
  • [ISSN] 1874-1754
  • [Journal-full-title] International journal of cardiology
  • [ISO-abbreviation] Int. J. Cardiol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


89. Bogov B, Lubomirova M, Kiperova B: Biopsy of subcutaneus fatty tissue for diagnosis of systemic amyloidosis. Hippokratia; 2008;12(4):236-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biopsy of subcutaneus fatty tissue for diagnosis of systemic amyloidosis.
  • BACKGROUND: The diagnosis of systemic amyloidosis is determined through histological material from biopsy of different parenchymal organs, which have high diagnostic and informative value, but hide a high risk of bleeding because of the accumulation of amyloid in the vessels' wall.
  • The first group consisted of patients with kidney biopsy proved amyloidosis compared to biopsy findings from other parenchymal organs.
  • The second group consisted of patients suspected having amyloidosis who underwent biopsies from various tissues or organs except kidney biopsy because there was contraindication.
  • RESULTS: One hundred fifteen biopsies of subcutaneous fatty tissue (SFT) were performed for the diagnosis of systemic amyloidosis.
  • In order to compare the data from the BSFT to the other known and practiced till the moment methods BSFT was performed in 54 patients with proved amyloidosis by KB.
  • In 14/19 the amyloidosis was typed as AA (74.2%) and 5/19 non-AA, probably AL (25.8%).
  • To reveal the meaning of so called screening-biopsy of subcutaneous fatty tissue for excluding accompanying amyloidosis in patients with significant proteinuria and/or uremia, dysglobulinemia, laboratory constellations for nephritic syndrome in immune nephropathies and chronic infections (Chronic Obstructive Lung Disease, purulent infections) with contraindications for kidney biopsy 61 screening BSFT were performed, accumulation of amyloid was defined in 37.
  • The method is enough informative for proving not only amyloidosis AL, but also for amyloidosis AA, in treating with KMnO4.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Amyloid. 2007 Sep;14(3):221-6 [17701469.001]
  • [Cites] Arthritis Rheum. 2006 Jun;54(6):2015-21 [16732553.001]
  • [Cites] JAMA. 1992 Nov 25;268(20):2946-51 [1433713.001]
  • [Cites] Mayo Clin Proc. 1975 Jan;50(1):29-40 [1110582.001]
  • [Cites] Arch Intern Med. 1988 Apr;148(4):988 [3355318.001]
  • [Cites] Arthritis Rheum. 1989 Jan;32(1):82-5 [2912466.001]
  • [Cites] Arch Intern Med. 1988 Apr;148(4):929-33 [2451487.001]
  • (PMID = 19158968.001).
  • [ISSN] 1790-8019
  • [Journal-full-title] Hippokratia
  • [ISO-abbreviation] Hippokratia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Other-IDs] NLM/ PMC2580046
  • [Keywords] NOTNLM ; aspiration of subcutaneous fatty tissue / biopsy of subcutaneous fatty tissue / histological diagnosis / systemic amyloidosis
  •  go-up   go-down


90. Picken MM: New insights into systemic amyloidosis: the importance of diagnosis of specific type. Curr Opin Nephrol Hypertens; 2007 May;16(3):196-203
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New insights into systemic amyloidosis: the importance of diagnosis of specific type.
  • PURPOSE OF REVIEW: This review aims to summarize recent developments in the area of systemic amyloidoses with emphasis on pathologic diagnosis.
  • RECENT FINDINGS: In recent years, management of amyloidosis has shifted from a purely supportive approach to quite diverse, radical and aggressive treatments.
  • The central issue is the understanding that treatment of systemic amyloidoses depends on the molecular type of the amyloid protein.
  • In the United States and the Western world, AL-amyloidosis is the most prevalent type of systemic amyloidosis, but hereditary amyloidoses are being diagnosed with increasing frequency; genetics also plays a role in a subset of familial AA amyloidoses.
  • While careful clinico-pathologic correlation is recommended for all patients with amyloidosis, it is, in itself, not a substitute for amyloid typing.
  • [MeSH-major] Amyloidosis / diagnosis. Kidney / pathology. Kidney Diseases / diagnosis
  • [MeSH-minor] Amyloid / metabolism. Amyloidosis, Familial / diagnosis. Amyloidosis, Familial / pathology. Coloring Agents. Congo Red. Diagnosis, Differential. Genetic Predisposition to Disease. Humans. Immunohistochemistry / methods. Serum Amyloid A Protein / metabolism. Staining and Labeling / methods

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. C.I. DIRECT RED 28 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17420662.001).
  • [ISSN] 1062-4821
  • [Journal-full-title] Current opinion in nephrology and hypertension
  • [ISO-abbreviation] Curr. Opin. Nephrol. Hypertens.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amyloid; 0 / Coloring Agents; 0 / Serum Amyloid A Protein; 0 / amyloid protein AL; 3U05FHG59S / Congo Red
  • [Number-of-references] 86
  •  go-up   go-down


91. Petrillo G, Catalano L, Petruzziello F, Padula S, Petrillo C, Caso P: [Amyloid cardiomyopathy: a link between cardiology and hematology. A case report of positive response to standard therapy]. G Ital Cardiol (Rome); 2007 Jun;8(6):371-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cardiac involvement in primary systemic amyloidosis, due to amassing of fragments of light chains, is detected in the majority of cases.
  • Primary systemic amyloidosis was diagnosed by abdominal fat pad biopsy.
  • Laboratory findings confirmed biopsy results, leading to the definite diagnosis of restrictive cardiomyopathy due to IgA kappa monoclonal gammopathy in primary systemic amyloidosis.
  • [MeSH-major] Amyloidosis / complications. Amyloidosis / diagnosis. Cardiomyopathy, Restrictive / complications. Immunoglobulin kappa-Chains / metabolism

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] G Ital Cardiol (Rome). 2007 Jun;8(6):377-80 [17633912.001]
  • (PMID = 17633911.001).
  • [ISSN] 1827-6806
  • [Journal-full-title] Giornale italiano di cardiologia (2006)
  • [ISO-abbreviation] G Ital Cardiol (Rome)
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


92. Chambers JK, Kanda T, Shirai A, Higuchi K, Ikeda S, Une Y: Senile systemic amyloidosis in an aged savannah monkey (Cercopithecus aethiops) with tenosynovial degeneration. J Vet Med Sci; 2010 May;72(5):657-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Senile systemic amyloidosis in an aged savannah monkey (Cercopithecus aethiops) with tenosynovial degeneration.
  • Senile systemic amyloidosis (SSA) is a rather common disease in elderly people, but it is very rare in animals, including nonhuman primates.
  • Pathological examination of a 26-year-old male savannah monkey (Cercopithecus aethiops) revealed systemic amyloidosis with severe cardiac fibrosis, and tenosynovial degeneration of the elbow and knee joints.


93. Oğuz H, Safak MA, Demirci M, Arslan N: Familial primary localized laryngeal amyloidosis in two sisters. Kulak Burun Bogaz Ihtis Derg; 2007;17(5):283-6
Genetic Alliance. consumer health - Amyloidosis Familial.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial primary localized laryngeal amyloidosis in two sisters.
  • Laryngeal amyloidosis is rare, accounting for less than 1% of all benign laryngeal tumors.
  • Although familial primary localized amyloidosis has been reported in other parts of the body, no familial cases have been reported in the larynx.
  • Primary localized laryngeal amyloidosis was detected in two sisters whose ages were 35 years and 38 years, respectively.
  • The results of endolaryngeal biopsies performed in both patients were reported as amyloidosis.
  • Further evaluations were negative for systemic amyloidosis.
  • [MeSH-major] Amyloidosis, Familial / diagnosis. Laryngeal Diseases / diagnosis

  • Genetic Alliance. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187988.001).
  • [ISSN] 1300-7475
  • [Journal-full-title] Kulak burun boğaz ihtisas dergisi : KBB = Journal of ear, nose, and throat
  • [ISO-abbreviation] Kulak Burun Bogaz Ihtis Derg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


94. Suzuki T, Uetsuka K, Kusanagi K, Hirai T, Nunoya T, Doi K: Hepatic Myelolipoma with systemic amyloidosis in a goose (Anser cygnoides domesticus). J Vet Med Sci; 2010 May;72(5):669-71
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic Myelolipoma with systemic amyloidosis in a goose (Anser cygnoides domesticus).
  • We report here a case of hepatic myelolipoma with systemic amyloidosis in a goose (Anser cygnoides domesticus), which died suddenly following the short history of weakness and greenish diarrhea.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526044.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


95. Gilad R, Milillo P, Som PM: Severe diffuse systemic amyloidosis with involvement of the pharynx, larynx, and trachea: CT and MR findings. AJNR Am J Neuroradiol; 2007 Sep;28(8):1557-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe diffuse systemic amyloidosis with involvement of the pharynx, larynx, and trachea: CT and MR findings.
  • Amyloidosis is a term applied to a diverse group of disorders that share the deposition of amyloid protein in various extracellular tissues.
  • Systemic amyloidosis may involve almost any organ system in the body including regions in the head and neck; however, pharyngeal involvement is rare, with only 12 cases having been previously reported.
  • Ten of these cases were localized disease, and only 2 cases were systemic amyloidosis.
  • We present the case of a patient with severe diffuse systemic amyloidosis with extensive involvement of the pharynx, larynx, trachea, lungs, eyelids, and breasts.
  • [MeSH-major] Amyloidosis / diagnosis. Magnetic Resonance Imaging. Respiratory System / pathology. Respiratory System / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846211.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


96. Dhingra S, Krishnani N, Kumari N, Pandey R: Evaluation of abdominal fat pad aspiration cytology and grading for detection in systemic amyloidosis. Acta Cytol; 2007 Nov-Dec;51(6):860-4
Hazardous Substances Data Bank. C.I. DIRECT RED 28 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of abdominal fat pad aspiration cytology and grading for detection in systemic amyloidosis.
  • OBJECTIVE: To evaluate the diagnostic efficacy of abdominal fat pad aspiration cytology as a screening procedure for systemic amyloidosis and to assess the clinical usefulness of semiquantitative grading criteria of fat pad amyloid deposits.
  • The deposits in the smears were compared with histologic evidence of amyloidosis in deeper tissues in 44 cases.
  • Follow-up biopsies from deeper tissues in 44 cases showed presence of systemic amyloidosis in 13 cases.
  • CONCLUSION: Fat pad aspiration cytology is a useful screening procedure for diagnosis of systemic amyloidosis.
  • Patients with grades 2 and 3 deposits may undergo suitable therapy for amyloidosis.
  • [MeSH-major] Adipose Tissue / pathology. Amyloidosis / diagnosis. Biopsy, Fine-Needle / methods

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18077977.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid; 0 / Coloring Agents; 3U05FHG59S / Congo Red
  •  go-up   go-down


97. Cholez C, Cuny JF, Pouaha J, Thomas P, Tromp G, Truchetet F: [Nail abnormalities and scleroderma-like lesions on the face associated with systemic amyloidosis]. Ann Dermatol Venereol; 2005 Mar;132(3):252-4
MedlinePlus Health Information. consumer health - Scleroderma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nail abnormalities and scleroderma-like lesions on the face associated with systemic amyloidosis].
  • INTRODUCTION: Mucocutaneous involvement in systemic amyloidosis occurs in 29 to 40 p. 100 of cases.
  • Nail abnormalities are infrequent in AL amyloidosis.
  • We report an original case of AL amyloidosis associated with cutaneous and integument alterations and scleroderma-like infiltration of the face.
  • DISCUSSION: We report an original case of a patient who developed two unusual cutaneous manifestations associated with AL amyloidosis.
  • [MeSH-major] Amyloidosis / pathology. Nail Diseases / etiology. Nail Diseases / pathology. Scleroderma, Localized / etiology. Scleroderma, Localized / pathology


98. van Gameren II, Hazenberg BP, Bijzet J, van Rijswijk MH: Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum; 2006 Jun;54(6):2015-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice.
  • OBJECTIVE: Aspiration of subcutaneous abdominal fat is a simple and fast method for detecting systemic amyloidosis; however, the sensitivity of this approach remains undetermined.
  • The aim of this study was to assess the accuracy of fat tissue aspiration for detecting systemic amyloidosis and the utility of this method in clinical practice.
  • METHODS: All consecutive patients with established and suspected systemic amyloidosis who attended our tertiary referral hospital between 1994 and 2004 underwent aspiration of subcutaneous abdominal fat.
  • RESULTS: One hundred twenty patients with established systemic amyloidosis were studied (38 with AA amyloidosis, 70 with AL amyloidosis, and 12 with ATTR amyloidosis).
  • One hundred sixty-two patients for whom there was a clinical suspicion of systemic amyloidosis were screened for amyloidosis by fat tissue aspiration and biopsy of at least 1 other tissue.
  • In 69 (43%) of these 162 patients, a diagnosis of amyloidosis was established, and in 66 (96%) of these patients, the results of fat tissue aspiration were positive.
  • CONCLUSION: Subcutaneous abdominal fat aspiration is the preferred method for detecting systemic amyloidosis, with sensitivity of 80% associated with use of a routine approach.
  • [MeSH-major] Amyloidosis / diagnosis. Subcutaneous Fat, Abdominal

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arthritis Rheum. 2007 Jul;56(7):2467; author reply 2468 [17599758.001]
  • (PMID = 16732553.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Woldemeskel M: Primary localized nodular cutaneous amyloidosis in a male neutered Golden Retriever. Dtsch Tierarztl Wochenschr; 2007 Dec;114(12):473-5
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary localized nodular cutaneous amyloidosis in a male neutered Golden Retriever.
  • Cutaneous amyloidosis occurs as primary localized form or secondary to systemic amyloidosis.
  • In dogs, cutaneous amyloidosis is reported in association with localized plasma cell proliferation or cutaneous extramedullary plasmacytoma.
  • Primary cutaneous amyloidosis is a very rare condition in dogs.
  • There is paucity of information and published report on primary nodular cutaneous amyloidosis in dogs.
  • This report describes a case of primary nodular cutaneous amyloidosis for the first time in a male Golden Retriever.
  • [MeSH-major] Amyloidosis / veterinary. Dog Diseases / diagnosis. Skin Diseases / veterinary

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18181363.001).
  • [ISSN] 0341-6593
  • [Journal-full-title] DTW. Deutsche tierärztliche Wochenschrift
  • [ISO-abbreviation] DTW. Dtsch. Tierarztl. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


100. Serra I, Oller B, Mañosa M, Naves JE, Zabana Y, Cabré E, Domènech E: Systemic amyloidosis in inflammatory bowel disease: retrospective study on its prevalence, clinical presentation, and outcome. J Crohns Colitis; 2010 Sep;4(3):269-74
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic amyloidosis in inflammatory bowel disease: retrospective study on its prevalence, clinical presentation, and outcome.
  • BACKGROUND: Systemic amyloidosis is a rare but life-threatening complication of inflammatory bowel disease (IBD), most cases being reported among Crohn's disease (CD) patients.
  • AIMS: To evaluate the prevalence of secondary systemic amyloidosis in a large IBD cohort of a referral centre, and to describe its clinical characteristics and outcome.
  • METHODS: Patients diagnosed with amyloidosis were identified among 1006 IBD patients included in the IBD database of our centre, and their medical records were carefully reviewed.
  • RESULTS: Among a total of 1006 IBD patients, 5 cases of amyloidosis were identified, all of them with CD, resulting in a prevalence of 0.5% for IBD and 1% for CD.
  • Two patients were treated with anti-TNF agents, showing a clinical improvement of their amyloidosis.
  • CONCLUSIONS: Secondary amyloidosis occurs mainly in long-lasting, complicated, Crohn's disease and seems to be as prevalent among IBD patients as previously reported.

  • Genetic Alliance. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
  • (PMID = 21122515.001).
  • [ISSN] 1876-4479
  • [Journal-full-title] Journal of Crohn's & colitis
  • [ISO-abbreviation] J Crohns Colitis
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down






Advertisement